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Triosephosphate isomerase (TPI) is a glycolytic enzyme that catalyzes the isomerization 
of dihydroxyacetone phosphate into glyceraldehyde 3-phosphate, a non-linear step in glycolysis 
not required for the production of pyruvate.  Dysfunction within TPI elicits a disease called TPI 
deficiency; a severe, rare, autosomal recessive disorder characterized by neurological 
dysfunction, shortened longevity, and hemolytic anemia.  Previous studies questioned whether 
this disease was caused by changes in metabolism or protein conformation.  To address this, we 
have used a genomic engineering strategy in Drosophila to study the relationship between the 
structure of TPI and pathology.  We have generated and analyzed novel high-resolution crystal 
structures of TPI mutant proteins, yielding basic insights into TPI dysfunction.  Our data suggest 
the pathogenesis of TPI deficiency is unrelated to its general role in metabolism.  Further, in 
vitro experiments demonstrate that a toxic Drosophila TPI allele is characterized by a defect in 
protein dimerization.  Using our genomic engineering system, we have generated several novel 
TPI alleles that further support the hypothesis that a conformational change at the dimer interface 
is sufficient to elicit TPI deficiency.  We have conclusively shown that gross TPI activity is not 
predictive of disease presence or severity.  Finally, we have identified a synaptic defect caused 
by a dimer interface mutant that we propose is the source of neurological dysfunction in 
Drosophila and TPI Deficiency patients. 
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Table 1. Summary of genomically engineered triosephosphate isomerase alleles. 
Allele name Homozygous 
viability 
Protein 
levels 
Lysate 
isomerase 
activity 
Mechanical 
stress 
sensitivity 
Thermal 
stress 
sensitivity 
Longevity Known or 
Hypothesized 
affect 
dTPI
+
 Viable +++ +++ None None +++ WT 
dTPI
∆cat(K12M)
 Lethal +++ n.d. n.d. n.d. n.d. Prevents 
catalysis 
dTPI
T74R
 Reduced + ++ +++ +++ + Alters dimer 
interface 
dTPI
G75E
 Reduced + ++ +++ ++ + Alters dimer 
interface 
dTPI
T74R,G75E
 Reduced + ++ +++ +++ + Alters dimer 
interface 
dTPI
M80T
 Viable ++ + ++ + ++ Alters dimer 
interface 
dTPI
R188A
 Lethal + n.d. n.d. n.d n.d. Breaks salt 
bridge 
dTPI
R188L
 Lethal + n.d. n.d. n.d. n.d. Breaks salt 
bridge 
dTPI
R188S
 Lethal + n.d. n.d. n.d. n.d. Breaks salt 
bridge 
dTPI
R188K
 Viable +++ n.d. None None n.d. Maintains salt 
bridge 
hTPI
+
 Viable +++ +++ None None +++ WT 
hTPI
T74R
 Lethal n.d. n.d. n.d. n.d. n.d. Alters dimer 
interface 
hTPI
G75E
 Lethal n.d. n.d. n.d. n.d. n.d. Alters dimer 
interface 
hTPI
T74R,G75E
 Lethal n.d. n.d. n.d. n.d. n.d. Alters dimer 
interface 
hTPI
M80T
 Viable ++ + + + ++ Alters dimer 
interface 
hTPI
I170V
 Viable +++ + + + +++ Alters lid 
conformation 
  
 
 
 1 
1.0  INTRODUCTION 
Over the course of evolution, biology has frequently recycled and repurposed protein 
conformations for roles other than their original function.  One of the greatest examples of this 
repurposing of protein structure has been the tertiary structure known as the triose isomerase 
(TIM) barrel.  The TIM barrel was first described in triosephosphate isomerase (TPI), but has 
since been found to be shared by over one hundred functionally diverse enzymes (2).  From 
endonucleases (3), to subunits of the K
+
 channels (4), to phospholipase signaling enzymes (5), 
this diversity clearly demonstrates the versatility of this structure.  Further, the concept of 
multifunctional protein structures has similarly been supported by work over the last few 
decades, revealing the oversimplification of the one protein–one function idea, similar to that of 
the one gene–one enzyme hypothesis.  These additional functions are often regulated by post-
translational modifications, subcellular localization, secretion, differential expression, and 
oligomerization (6).  Many enzymes, such as pyruvate kinase (PK), have been demonstrated to 
perform additional activities upon changes in their oligomerization.  As a monomer, PK is able 
to bind and inhibit the signaling of thyroid hormone receptors in the cytosol (7); yet upon 
oligomerization, PK loses its ability to sequester thyroid hormone receptors and becomes a full 
participant in glycolysis (8).  Other examples of novel functions are based on subcellular 
localization; hemoglobin is a well-described molecule capable of binding gases, and used to 
transfer oxygen throughout an organism.  However, recent studies in the vasculature have 
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identified it as a regulator of nitric oxide signaling (9,10), due to its ability to bind and sequester 
NO in a spatial and temporal manner (11).  These examples are beautiful illustrations of how 
evolution has recycled and reused elements of biochemistry to arrive at our current biological 
complexities, and emphasize the ability of proteins to function in numerous capacities. 
In my dissertation work I have utilized the Drosophila model system to examine the 
complexities of the glycolytic enzyme, TPI.  I have established a genomic engineering approach 
to examine the functional properties of TPI and the pathogenesis of its associated disease, 
triosephosphate isomerase deficiency.  Collectively, my work examines the structure of TPI, and 
how changes in this structure may induce pathophysiology.  I believe my work supports a role 
for localized TPI catalysis at the synapse, though the precise mechanism is still unclear.  In this 
introduction I will briefly review the literature surrounding the known biochemistry of TPI, the 
pathology associated with TPI deficiency, and the utility of Drosophila and the genomic 
engineering methodology. 
1.1 TRIOSEPHOSPHATE ISOMERASE 
1.1.1 Protein structure and catalysis 
Triosephosphate isomerase (TPI) is a non-linear enzyme of the glycolytic pathway.  Within 
glycolysis, TPI is located immediately downstream of aldolase and parallels glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) [Figure 1].  TPI catalyzes the isomerization of 
dihydroxyacetone phosphate (DHAP) into glyceraldehyde 3-phosphate (GAP), as GAP is the 
necessary 3-carbon substrate capable of producing pyruvate.  This isomerization reaction 
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requires a catalytic base to initiate deprotonation of the DHAP substrate (12).  If allowed to 
proceed non-enzymatically using a chemical base, the slow deprotonation of DHAP would result 
in equivalent levels of GAP and an enodiolate intermediate, whose kinetics would deviate 
thermodynamically toward the production of a reactive Schiff base, methylglyoxal (13).  
Methylglyoxal contains a highly reactive aldehyde group that will readily adduct to proteins and 
DNA, thereby causing cellular damage (14).  The positioning of the catalytic residues in TPI 
facilitates an extremely rapid deprotonation of DHAP, yet if left unguided this reaction would 
also generate methylglyoxal.  To inhibit the formation of this toxic byproduct and bias the 
formation of GAP, TPI utilizes a “lid” mechanism which gates the diffusion of any reaction 
intermediates, thereby directing nearly all of the substrate to the appropriately isomerized 
product (13).   
To understand the catalysis of TPI, you must understand its structure.  TPI utilizes a TIM 
barrel base, upon which its catalytic properties have been built (15).  The TIM barrel is a 
commonly used enzymatic tertiary structure which involves alternating beta sheets and alpha 
helices for the production of a stable barrel.  This stable foundation coordinates the positioning 
of looped segments between the beta sheet/alpha helix stretches, and these loops are what give 
each TIM barrel enzyme their respective functional properties.  In TPI, several loops contain 
elements which assist with enzyme dimerization as well as the formation and support of the 
catalytic site (16). 
TPI has traditionally been thought of as an obligatory homodimer, as monomeric versions 
of the protein have yet to be identified in vivo and the catalysis of the enzyme is greatly 
influenced by dimerization.  Indeed, targeted modifications to the TPI dimer interface have been 
generated and characterized in vitro, with all iterations displaying a significant reduction in 
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catalysis (17-19).  These catalytic changes are in stark contrast to the diffusion-limited rates 
achieved upon appropriate dimerization (20).  Structural analyses have revealed that the 
dimerization of TPI helps support the formation of a rigid catalytic pocket (18).  In particular, 
several critical catalytic residues, such as N10 and K12, are supported by hydrophobic 
interactions at the dimer interface (18,19).  Without appropriate positioning in monomeric forms 
of the enzyme, these residues and the catalytic lid appear flexible.  Similarly, molecular 
simulation experiments have concluded that the catalytic residue H95 is coordinated by a 
hydroxyl group extending from a threonine as part of the partner dimer (21).  This hydroxyl 
group is part of the critical loop 3 of the enzyme, which forms a majority of the dimer interface 
surface area.  The tip of TPI loop 3, of which T74 is a key component, reaches into and stabilizes 
the catalytic site of its dimer partner (18,22).  Mutations in T74 and its neighbor G75 have been 
shown to be sufficient to disrupt dimer formation (19).  These residues and their pathogenic 
propensities will be analyzed in Chapter 3. 
Although dimerization has been well-established as a means to regulate the catalytic 
capacity of TPI, little has been done to study how catalysis may convey changes back to the 
dimer interface. One hint of this type of bidirectional relationship was revealed by (23) wherein 
the authors studied the capacity of thiol-targeted reagents to adduct dimer interface cysteines.  It 
was established that occupation of the enzyme protected the buried dimer interface cysteines 
from modification.  Conversely, enzyme without substrate – a more dynamic open conformation 
– exhibited substantial susceptibility for modification by the chemical agents methylmethane 
thiosulfonate (MMTS) and 5,5-dithiobis(2-nitrobenzoate) (DTNB) (23).  These data would 
suggest the capacity for the catalytic site to modulate accessibility of buried dimer interface 
residues.  If occupancy of the enzyme were truly to influence dimerization and stability, it is 
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tempting to think that this may be a self-regulatory mechanism for sensing its necessity and 
regulating turnover.  Through structural and biochemical analyses, I have established that 
changes in lid conformation are capable of influencing dimerization through the reinforcement of 
a trans-monomeric hydrogen bond network.  This bidirectional relationship between the dimer 
interface and catalytic site will be explored and discussed in Chapter 4. 
 
 
Figure 1.  Triosephosphate isomerase and its related metabolic pathways.  A) The de novo glycerol 
synthesis pathway, B) glycolysis, and C) the pentose phosphate pathway.  Only critical substrates are 
indicated. 
1.1.2 TPI and its metabolic pathways 
TPI sits at the crux of glycolysis and enhances its bioenergetic capacity [Figure 1].  The 
additional GAP molecule generated through the isomerization of DHAP contributes a second 
three-carbon substrate for the production of adenosine triphosphate (ATP), the reduced form of 
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nicotinamide adenine dinucleotide (NADH), and pyruvate (24).  The two molecules of ATP 
generated through this molecule of GAP result in a net gain in ATP for the entire glycolytic 
process.  GAPDH, the next enzyme in glycolysis following TPI, generates NADH from the 
oxidation of GAP (24).   
The relationship between TPI and NADH however does not stop at its ability to help 
generate GAP simply for glycolysis; TPI is also involved in the glycerol 3-phosphate (G3P) 
proton shuttle (25).  Cytosolic and mitochondrial pools of NADH are discrete, with the 
exceptions of the malate-aspartate and glycerol 3-phosphate shuttles (25).  NADH generated in 
cytosol is oxidized by glycerol 3-phosphate dehydrogenase (GPDH) with DHAP to form 
glycerol 3-phosphate (24).  This glycerol is the backbone of most phospholipids and 
triglycerides, but can also pass through the inner mitochondrial membrane where mitochondrial 
GPDH oxidizes G3P and FAD
+
 is reduced to FADH2 and DHAP (24).  If TPI were inactive, one 
would predict that this irreversible transfer mechanism would be enhanced through the 
accumulation of DHAP, possibly leading to a depletion of cytosolic NADH.  Again, although 
TPI’s role in this process is peripheral, its inhibition through catalysis or mislocalization could 
result in a selective depletion of cytosolic NADH pools, potentially influencing pyridine 
effectors. 
In addition to its intimate relationship to glycolysis, TPI peripherally participates in the 
pentose phosphate pathway (PPP) through its relationship with GAP (24).  GAP is a product of 
the PPP, which generates reducing cofactors (nicotinamide adenine dinucleotide phosphate – 
NADPH) and precursors of nucleotides and aromatic amino acids (24).  In this way, the PPP 
could be a means to bypass initial inefficiencies in glycolysis, and inhibition of TPI is predicted 
to increase glucose 6-phosphate flux from the glycolytic pathway to the PPP (26).  Within the 
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PPP, this 6 carbon molecule will be broken down, yielding NADPH, ribose 5-phosphate, and 
erythrose 4-phosphate (24).  NADPH is a key electron donor for the regeneration and 
maintenance of glutathione and the cellular redox environment as well as signaling enzymes 
such as NADPH oxidases.  Ribose 5-phosphate can be shunted to help generate nucleotides, 
while erythrose 4-phosphate can be diverted for the production of aromatic amino acids (24).  
However, the progression toward the production of nucleotides or amino acids is regulated by 
their respective anabolic enzymes; in the absence of a need for either of these constituents, the 
ribose 5-phosphate and erythrose 4-phosphate would be further catabolized through the PPP to 
generate fructose 6-phosphate and GAP.  GAP can be handed back to the glycolytic pathway 
through GAPDH while fructose 6-phosphate can be reused by the PPP to generate more GAP, or 
fed directly back into glycolysis (24).   
1.1.3 Important catabolic products 
Through directly- or indirectly-linked pathways, TPI yields three molecules of 
biochemical importance: ATP, NADH, and NADPH.  The function of ATP as a phosphate donor 
has been well-established in the literature as a central molecule in biochemistry, yet NADH and 
NADPH are still gaining appreciation for their biological activities.  Previously, NADH was 
largely thought to feed the electron transport chain (ETC) of mitochondria simply for the 
production of ATP, yet biochemists are finding increasingly influential roles for this type of 
electron donor species in signal transduction events.  One well-established pathway through 
which this molecule can modulate biology has been control over the Sirtuin family (27,28).  The 
Sirtuins bind the unreduced form of NAD
+
 to induce the deacetylation of other transcription 
factors and histones (29).  Through these means, local NAD
+
 gradients can regulate gene 
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transcription, and enhancement of this capacity has been shown to phenocopy the longevity 
enhancement seen in caloric restriction models of aging (30-34).  Indeed, we see a progressive 
increase in NAD
+
 relative to NADH in our TPI
M80T
 animals (35), and if recapitulated in our 
dimer mutants, a putative increase in NAD
+
 is possibly the means through which we see a 
substantial increase in the longevity of our heterozygotes animals (Chapter 3), though such 
hypotheses are as of yet untested.   
Additionally, both NAD
+
 and NADP
+
 have been shown to modulate K
+
 channel activity 
(36).  NAD
+
 has been demonstrated to bind the cytoplasmic domain of Slo2 K
+
 channels (BKCa) 
(37), leading to a 2-fold increase in open probability.  Additionally, the beta subunit of voltage-
gated potassium channels (Kvβ) binds both NAD+ and NADP+, but not their reduced 
counterparts (38).  As mentioned previously, the KVβ proteins are members of the aldo-keto 
reductase family of proteins and in an extremely interesting coincidence, utilize a TIM barrel 
structure to bind pyridine nucleotides (4).  This binding event removes their inactivating 
influence on the alpha units of the channel, thereby facilitating K
+
 flux (39,40).  Finally, the 
transient receptor potential M2 channel (TRPM2) has been shown to be redox sensitive (41), 
with applications of NAD
+
 increasing permeability (42).  Direct binding experiments have been 
performed (41), though some contend these results are controversial (43).  Regardless, it is clear 
that there is an increasing appreciation for the cytosolic activities of these molecules, and further 
work detailing the importance of local changes in redox pyridines will be extremely interesting. 
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1.2 TRIOSEPHOSPHATE ISOMERASE DEFICIENCY 
1.2.1 A historical perspective on TPI deficiency and its evolutionary maintenance 
Schneider and colleagues first identified a disease associated with triosephosphate 
isomerase back in the 1960s (44).  In this seminal article, a small cohort of individuals was 
examined in an isolated area of Louisiana wherein a number of children were identified with a 
curious collection of symptoms.  The affected infants/children often displayed signs of hemolytic 
anemia, weakened immune responses, and progressive neuromuscular impairments.  The 
children would exhibit an odd collection of periodic dystonia, episodic seizures, and progressive 
weakness and flaccidity in their extremities.  These behaviors often would continue to progress 
until the point of early death, though the cause of death was often ascribed to the persistent 
infections the patients experienced.  Pedigree analyses suggested an autosomal recessive disease, 
and although no consanguinity was initially described, the children’s parents admitted to being 
‘almost certain that they were related in some way’ (26).  Through metabolic experiments it was 
revealed that the hemolytic anemia experienced by these patients was likely derived from 
reduced TPI activity.  Later, molecular studies of these and similar patients revealed that the 
disease was caused by a collection of mutations within the promoter and coding regions of the 
TPI gene (45). 
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Figure 2.  Structure of triosephosphate isomerase highlighting residues affected by human disease-
associated missense mutations.  TPI dimer is shown as a cartoon, with one monomer colored blue and the 
other gold.  Known human mutations are plotted structurally and shown as white with colored elements in 
sticks.  The active site is labeled with DHAP, shown in spheres.  Labels indicate the residues and their 
changes.  Structure shown is WT from yeast, crystallized with DHAP bound in the active site. PDB accession 
code: 1NEY (46). 
 
Typically, patients are genetically characterized as transheterozygotes, with a point 
mutation paired with one of several null alleles.  These null alleles are most often elicited 
through the introduction of a premature stop codon, with the resulting transcript left untranslated 
due to nonsense-mediated decay (45,47,48).   Indeed, hypomorphic alleles have been widely 
described in the general population, though no individuals have yet been identified with 
homozygous null mutations.  A population screen of infant mortality suggested that a 
homozygous null condition is embryonic lethal, and these data are supported by similar 
observations in rodents and Drosophila (49-52).  Therefore to achieve viability, some degree of 
activity must be retained – these observations are supported by the homozygous lethality found 
in our catalytically inactive mutants described in Chapter 2.  
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Of particular interest to population geneticists has been the wide geographic prevalence 
of the toxic E104D allele.  Flanking polymorphisms were used to establish that the E104D allele 
likely arose roughly 1000 years ago (53,54).  The genetic maintenance of this mutation has been 
curious, and many suggested could likely be indicative of an advantageous hypomorphic loss-of-
function.  Indeed, population surveys of hemocyte TPI activity and gene integrity revealed a 
substantial rate of promoter mutations in African American populations (41%) (55).  It is still 
unclear exactly what advantageous properties are conveyed through a hypomorphic condition, 
though the simplest explanation would be one of mild metabolic restriction, and again could be 
related to the genomic signaling properties of NAD
+
 accumulation.  A human population 
analysis of the activity rates of 11 metabolic enzymes identified TPI as enriched in functional 
deficiencies, second only to pyruvate kinase, the second most prevalent glycolytic enzymopathy 
(56).  Caloric restriction has emerged in the field of aging as one of the most reliable means of 
extending lifespans.  Our results in Chapter 3 detail the dramatically increased longevity in 
Drosophila heterozygous for dimer interface mutations.  These data are the first to demonstrate a 
definitive advantage conveyed by heterozygous loss-of-function TPI alleles in a uniform genetic 
background, and support the conclusions of decades of population genetics. 
1.2.2 Known TPI deficiency mutants and investigative studies 
Disease-associated mutations have been described in several functionally relevant, yet 
diverse structural locations.  Residues affected by disease mutations are plotted on an image of 
the enzyme in Figure 2.  To date, the only mutations that have been identified as homozygotes 
are those resulting in E104D and V231M (45,48).  Further, only E104D, V231M, and F240L 
have been demonstrated to be sufficient to elicit TPI deficiency in human patients; C41Y, I170V 
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and G122R have never been identified in patients without accompanying the E104D allele 
(45,48).  Due to the rarity of this disease it is unclear whether these mutations are viable, lethal, 
pathogenic, or simply lack sufficient consanguinity; this topic will be addressed in Chapter 4.  
The most widely identified mutation to date has been a Glu-to-Asp change at position 104 
(E104D) (26).  This mutation occurs at the dimer interface of the enzyme and has been 
associated with disease in a multitude of different allelic contexts; homozygous and trans-
heterozygous in combination with null alleles as well as other point mutations. 
One such trans-heterozygote case provided a unique opportunity within the TPI 
deficiency field – in 1993 a group of clinical researchers identified two genotypically similar 
brothers, one with neurological dysfunction and another healthy and normal (57).  The brothers 
each had an allele bearing the F240L point mutation and the other a null.  These phenotypically-
contrasting patients spurred a number of investigations into possible biological explanations for 
the neurological symptoms.  Using primary tissue samples, (erythrocytes taken from patients) the 
research group identified an increase in plasma membrane calcium ATPase levels (PMCA: 2-3 
fold increase) and acetylcholinesterase activity (~30%) in the affected compared to the symptom-
free brother (58).  Later experiments working with the same F240L mutation identified enhanced 
association of the mutant variant of the enzyme to the plasma membrane of erythrocytes as well 
as microtubules, though this enhancement was admittedly modest (59).  To explain these 
observations, the authors proposed a gain-of-function model; wherein mutations in TPI caused 
enhanced binding to microtubules and PM.  The authors also demonstrated a reduction in TPI 
activity upon the addition of microtubules, which they proposed would further exacerbate the 
deficiencies found in patients (59).  These hypotheses have largely gone unexplored in the last 
decade, though data discussed in Chapters 2,3 and 4 strongly suggest a loss-of-function disease 
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mechanism rather than a gain-of-function.  Indeed, the recessive nature of this disease would 
support such a conclusion, and no published or unpublished results have indicated a toxic gain-
of-function in any TPI alleles. 
1.3 TPI DEFICIENCY IN MODEL ORGANISMS 
1.3.1 Studies in mice and yeast 
Given the rarity of this disorder, pathogenic studies of TPI deficiency have been difficult.  
The majority of research surrounding the disease has thus far focused on primary tissue samples 
derived from a select few patients.  These studies are inherently limited to descriptive analyses, 
precluding hypothesis-driven research.  The dearth of available patient tissues has severely 
limited the ability to study the basis of the neurological phenotypes associated with TPI 
deficiency.  To this end, the development of a tractable model system would significantly impact 
the field, yet the genetics of such a system have proven difficult to manage.  The homozygous 
lethality, and dose-dependent loss-of-function nature of TPI deficiency necessitates gene 
replacement or mutagenesis of the endogenous locus.  As a result, few model organisms exist 
with which to examine TPI deficiency.  Murine and Drosophila TPI knockouts and null alleles 
have been generated, but proven lethal (50,60).  One mouse point mutant of TPI, D49G, has 
recently been identified in a biased screen for erythrocyte enzyme mutations (61), though this 
study focused on hematological parameters of the animals, and no behavioral defects were noted. 
Work in the yeast species S. cerevisiae has proven informative for the in vivo 
biochemical characterization of the various human mutations (62).  Indeed, Ralser and 
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colleagues were the first to establish that the most prevalent mutation, E104D, exhibited an odd 
dimerization phenotype using the yeast-two-hybrid approach (62).  These data were later 
corroborated by a more focused structural analysis which deduced that the dimerization 
phenotype was due to a miscoordination of dimer interface water molecules via the shortening of 
the glutamic acid residue (63).  This evidence set precedent that TPI pathology could be due to a 
reduction in dimerization, though a pathophysiological mechanism was still unclear. 
1.3.2 Studies in Drosophila  
1.3.2.1 Drosophila neurobiology 
Around the same time as the Ralser publication, two independent groups of Drosophila 
biologists identified the same Met-to-Thr substitution at position 80 (M80T) in TPI (50,64).  This 
M80T mutation led to neuropathology and behavioral dysfunction.  These mutants were 
identified in a chemical mutagenesis screen for aberrant behavior, and were characterized with 
two typically distinct behaviors: thermal stress and mechanical stress sensitivity.  The former 
behavior was pioneered by Ganetzky and colleagues as a phenotype enriched for neurological 
dysfunction.  This behavioral test uses elevated temperature to stress the animals to a non-
permissive level, and the subjects are monitored for seizures or paralysis relative to appropriate 
genetic controls.  The basis for this stress-dependency include a trio of factors which are believed 
to lead to the aberrant behavior: i) elevated temperature increases basal Drosophila neural 
activity, ii) increased temperature enhances sensory inputs to the central nervous system, and iii) 
elevated temperature could negatively influence thermolabile proteins (65-69).  This thermal 
stress methodology has been used in conjunction with forward genetic screens to reveal 
mechanisms of neurological function, such as voltage-gated ion channels and their associated 
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transcriptional regulators (69,70), vesicle fusion/recycling proteins (71), and regulators of 
synapse development (72,73), among others.  Of particular interest is the nature of the aberrant 
behavior and the time of onset; the faster the time of onset the more germane the mutant is likely 
to be to neurological function (72).   
Comparatively, the latter phenotype, mechanical stress sensitivity, has been thoroughly 
examined by Tanouye and colleagues as an insect analog of mammalian seizures (74,75).  
Supporting this assertion, recent work in our laboratory has established that strobe light 
stimulation is sufficient to phenocopy mechanical stress-dependant phenotypes, suggesting that 
overstimulation of sensory inputs is both necessary and sufficient to elicit these behaviors (76).  
Indeed, targeted electrophysiology experiments with mechanical stress-sensitive mutants have 
demonstrated fundamental characteristics of seizures: electrically-inducible uncontrolled activity 
followed by refractory periods (77-79).  These “seizures” are threshold events, capable of being 
achieved in even wild type animals with enough stimulation.  Using a modified Drosophila giant 
fiber preparation, Tanouye and colleagues established that many anti-epileptic drugs were 
capable of increasing the threshold to seizure activity in wild type and several mechanically 
stress sensitive mutant alleles (80-84).  These results were leveraged further to identify novel 
putative therapeutic targets for treating epileptic patients, a forward genetic approach badly 
needed in the epileptic community.  These experiments have been extremely fruitful for basic 
research into the causes of epilepsy and potential therapeutic strategies, often revealing an 
intimate link between metabolism and seizure activity. 
Collectively, characterization of a Drosophila TPI allele with both of these behaviors 
corroborated the diverse spectrum of abnormal neuro- and neuromuscular symptoms seen in 
human patients.  The TPI
M80T
 phenotypes suggested the potential for underlying neuropathology, 
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and indeed evidence was found of both peripheral and central neuropathy in this Drosophila 
model of TPI deficiency (50), again, much like in the human patients.  To date, Drosophila are 
the only model organism to effectively recapitulate the neurological dysfunction seen in human 
patients (48).   
1.3.2.2 Drosophila reveal mechanisms of pathologic protein regulation 
Yet the similarities do not end with the neurological phenotypes displayed by the 
animals; the TPI
M80T
 allele shares many biochemical similarities with the mutant human proteins.  
Importantly, all of the severely pathological human TPI mutations exhibit thermolability 
(26,45,48).  Thermolability of a protein establishes a susceptibility to inactivation due to heat 
stress, and this could be indicative of stability/conformational defects within the protein.  
Previous studies in our laboratory have established that TPI
M80T
 is found at reduced protein 
levels, while transcript levels actually increase (85); collectively these data suggest a defect in 
translation or stability of the protein which causes cellular depletion.  Later examinations 
revealed that molecular chaperones, heat shock protein 70 and 90 (Hsp70, Hsp90), were 
preferentially bound to the TPI
M80T
 protein (86).  The pathologic relationship between this 
Drosophila mutant and these chaperones was established through pharmacologic and genetic 
inhibition, which both moderately attenuated TPI
M80T
 levels and also helped ameliorate some of 
the behavioral phenotypes seen in the mutants.  Experiments seeking to examine the possible 
relationship between the chaperones and protein levels established that proteosomal inhibition, 
genetic or pharmacologic, was sufficient to increase TPI
M80T
 protein levels (86).  These results 
concluded that reduced TPI levels in TPI
M80T
 were in part attributable due to increased protein 
degradation.  Importantly, reduced TPI levels have been detected in primary human tissue from 
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patients.  These observations set the stage for us to question whether the activity of the enzyme 
or its presence was most critical to the disease phenotypes in our animals (Chapter 2). 
1.3.2.3 Drosophila and TPI deficiency redox changes 
The Drosophila system also recapitulates the lack of ATP depletion found in patient 
tissues (87-89), and these data have led us to question the pathogenic importance of general 
metabolism in TPI deficiency (Chapter 2,3).  Reduced glycolytic flux is known to be 
compensated by rerouting substrates from glycolysis to the PPP (90), and this detour is likely 
controlled by two possible mechanisms; i) a buildup of DHAP substrate to inhibit aldolase, 
and/or ii) oxidative stress-induced redirection of metabolites (90-92).  We find it likely that both 
mechanisms are influencing metabolic rerouting, as DHAP has been shown to accumulate in 
patient tissues with reduced TPI activity (57), and oxidative stress has been demonstrated to 
target redox-sensitive glycolytic enzymes to reroute glycolytic intermediates through the PPP 
(91).  Further, the TPI
M80T
 allele has been characterized as exhibiting mitochondrial oxidative 
stress (35).   
Previous work by our lab and others suggested that mitochondrial redox changes could be 
due to an accumulation of a toxic byproduct of DHAP (35,64,93).  If allowed to accumulate, 
DHAP can be non-enzymatically converted into the reactive Schiff base, methylglyoxal (MG).  
Hrizo and colleagues suggest that the accumulation of this advanced glycation end-product 
(AGE) could be responsible for inducing the mitochondrial stress exhibited in the TPI
M80T
 
animals (94,95).  To address this possibility, we have generated knockouts (KOs) of the initial 
glyoxylase enzyme responsible for detoxifying the organism of MG.  These glyoxylase KO 
animals failed to recapitulate our mutant TPI phenotypes [data not shown].  Further, gross 
measurements of AGEs have not revealed an obvious contribution to the pathology of the 
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animals, as changes in genetic background have a more dramatic effect on AGE accumulation 
than the inhibition of TPI or the glyoxylase enzyme [data not shown].  This work is still ongoing 
in the laboratory, yet the initial experiments suggest that MG is not a primary contributor to TPI 
deficiency pathology.   
Still, TPI deficiency-associated changes in redox status provide a platform to ask a 
number of intriguing questions surrounding the relationship between glycolysis, the PPP, and 
mitochondrial redox changes.  It has been demonstrated that inhibition of TPI increases PPP flux 
(90,91), yet this increase in PPP and production of NADPH protects the cells from redox 
changes in only certain human disease-associated TPI mutants (62).  Further, the simple 
conclusion that mitochondrial reactive oxygen species (ROS) increases as a function of 
glycolytic flux inhibition is also unclear.  Is the cell compensating for reduced glycolytic ATP 
production by upregulating oxidative phosphorylation, or are changes in ROS elicited by a non-
metabolic mechanism?  Why can activation of the PPP in certain TPI mutants counter this 
putative increase in mitoROS; does this suggest differences in pathogenesis?  Are changes in 
redox status in the cell a toxic byproduct of reduced glycolytic flux, or a purposeful signal from 
the mitochondria to reroute glycolytic metabolites through the PPP?  Noting the modest changes 
in TPI pathology elicited through redox modulation (35), I propose that mitochondrial ROS in 
the TPI
M80T
 animals is likely signaling a purposeful rerouting of metabolic substrates toward the 
PPP.  However, it is not clear whether these observed redox changes in pyridines are derived 
from mitochondrial or cytosolic sources.  Later discussions will focus on the putative impact of 
changing cytosolic redox status, with a focus on local changes in pyridine oxidation at the 
plasma membrane [Chapter 3,5]. 
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1.4 DROSOPHILA GENOMIC ENGINEERING 
Work spanning the last decade has outlined Drosophila as a model organism capable of 
recapitulating the neurological dysfunction seen in human TPI deficient patients 
(1,35,50,64,85,86).  This observation provided a unique opportunity to perform hypothesis-
driven experiments aimed at delineating the pathogenic mechanism through which this 
neurological dysfunction occurs.  Given that TPI deficiency is a dose-dependent loss-of-function 
disorder, traditional transgenic modulations – often considered the strength of the Drosophila 
system – were deemed inadequate.  Fortunately, recent advances in Drosophila homologous 
recombination and genomic engineering technology provided a unique opportunity to study this 
disorder. 
For several years Drosophila homologous recombination (HR) technology lagged behind 
that of yeast and murine systems.  This was fortunately changed roughly 13 years ago by the 
work of Rong and Golic (96).  In this seminal study, the authors first outlined an efficient 
methodology for performing ends-out and ends-in targeting in Drosophila.  The HR system was 
designed to utilize elements encoded entirely by the genome, requiring no injections of pre-
linearized DNA.  Shortly thereafter, a number of groups within the Drosophila community began 
pursuing phiC31-mediated integration as a means to overcome positional variability in transgene 
expression (97,98).  These studies stemmed from an older challenge with random transposon-
mediated transgenesis, wherein genomic changes in transgene positioning could influence 
expression of the construct.  These expression/position based complications made comparisons 
between two constructs difficult, necessitating numerous replicates and control experiments.  To 
anticipate this problem, geneticists conscripted a viral integrase technology known as the phiC31 
integrase system.  The complementary integrase sites, attP and attB, were used in conjunction to 
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ensure site-specific and directional transgenesis.  First, an attP site was placed on a traditional 
transposon and integrated into the genome through standard p-element transgenesis.  Once 
placed, this site became an anchor for future phiC31-mediated transgenesis with the attP 
directing uniform localization of all transgenic permutations.  Constructs containing the 
complementary attB site were generated and injected into the embryos expressing germ-line 
phiC31 integrase to mediate inheritance. 
A major advance in Drosophila genetics was ushered in by uniting the HR and phiC31 
genomic techniques.  A few years ago Huang and colleagues (99,100) utilized the knock-in 
technology pioneered in HR to replace endogenous genes with attP engineering sites.  The 
directed placement of these phiC31 landing sites opened a window into the originally targeted 
gene, making it amenable to future modifications [Schematic shown in Figure 5].  This genomic 
engineering (GE) strategy has been an extremely valuable tool for the meticulous evaluation of a 
specific gene.  Yet the technology’s true utility was in studying highly dose-dependent loci, 
where traditional transgenic expression could introduce over/under-expression and 
misexpression complications.  The importance of using the endogenous regulatory machinery 
was illustrated as the Hong group was able to tag developmentally critical proteins of interest, 
revealing novel functions due to the lack of typical untoward effects associated with transgenic 
manipulations (101).  To this end, the two gene loci I have worked on in my graduate career have 
both been characterized as dose-dependent.  In collaboration with the Hong group we have 
targeted the ATPa gene encoding the major catalytic subunit of the Na,K-ATPase [unpublished], 
and TPI (1).  The work I will describe in this document will be primarily composed of alleles 
generated using GE of the TPI locus.  It is critical to note the beauty of this genetic approach, as 
all of these alleles were generated in a uniform background.  Therefore the key differences 
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between the animals will be the subtle allelic changes made through our targeted modifications.  
This genetic approach is unparalleled, allowing me with confidence to say that my thesis work 
truly is a structure-function analysis within the context of a whole organism. 
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2.0  EVIDENCE OF A NON-CATALYTIC FUNCTION OF TRIOSEPHOSPHATE 
ISOMERASE CRUCIAL TO BEHAVIOR AND LONGEVITY 
2.1 ABSTRACT 
Triosephosphate isomerase (TPI) is a glycolytic enzyme that converts dihydroxyacetone 
phosphate (DHAP) into glyceraldehyde-3-phosphate (GAP). Glycolytic enzyme dysfunction 
leads to metabolic diseases collectively known as glycolytic enzymopathies. Of these 
enzymopathies, TPI deficiency is unique in the severity of neurological symptoms. The 
Drosophila sugarkill mutant closely models TPI deficiency and encodes a protein prematurely 
degraded by the proteasome. This result caused us to question whether enzyme catalytic activity 
was critical to pathogenesis of TPI sugarkill neurological phenotypes. To study TPI deficiency in 
vivo we developed a genomic engineering system for the TPI locus that enables the efficient 
generation of novel TPI genetic variants. Using this system we demonstrate that TPI sugarkill 
can be genetically complemented by TPI encoding a catalytically inactive enzyme. Further, our 
results demonstrate a nonmetabolic function for TPI, the loss of which contributes significantly 
to the neurological dysfunction in this animal model. 
 23 
2.2 INTRODUCTION 
Triosephosphate isomerase (TPI) is a homodimeric enzyme that functions in a non-linear step of 
glycolysis, converting dihydroxyacetone phosphate (DHAP) into glyceraldehyde 3-phosphate 
(GAP).  Both DHAP and GAP are produced from the catabolism of fructose 1,6-bisphosphate by 
the enzyme aldolase; however, only GAP can be utilized by the remaining steps in glycolysis.  
Therefore, TPI is responsible for the net gain of glycolysis-derived ATP as well as the 
production of an extra molecule of pyruvate per molecule of glucose.  This enhancement of 
glycolysis plays an important role in the bioenergetics of both aerobic and anaerobic metabolism.  
Mutations in TPI have been identified in humans that result in a disease known as TPI 
deficiency.  TPI deficiency is a recessive loss-of-function disease resulting from missense 
mutations in the gene.  The disease is clinically characterized by symptoms such as hemolytic 
anemia, cardiomyopathy, neurological dysfunction and degeneration, and premature death 
(26,45).  Pathogenic mutations can be found in various regions of TPI affecting either the 
promoter or coding sequence, and all patients suffering from TPI deficiency have been reported 
as having dramatically reduced TPI activity in vivo owing to changes in catalysis and/or enzyme 
stability (57,102,103).  Patients suffering from TPI deficiency may present with one or more of 
the previously described symptoms with no reliably predictive biochemical or structural 
characteristics ascribed to each phenotype or degree of severity.   
Drosophila are the only model system identified to date in which mutants have been 
shown to recapitulate the neurological phenotypes seen in human patients (50,64).  We have 
previously isolated an animal model of TPI deficiency known as TPI
sugarkill (sgk)
.  TPI
sgk
 is 
characterized by shortened lifespan, neurodegeneration, and conditional behavioral abnormalities 
(50) resulting from a missense mutation causing a methionine to threonine substitution (M80T).  
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The affected methionine is present near the dimer interface yet does not seem to result in a shift 
in monomer-dimer populations in vivo (85).  However, the TPI
sgk
 mutation has been shown to 
induce abnormal proteasomal degradation of TPI resulting in reduced total TPI protein (85,86).  
Interestingly, we have previously shown that this loss-of-function mutation can be attenuated by 
overexpressing mutant TPI
sgk
 (50).  This result caused us to question whether the presence of the 
enzyme or its catalytic activity was most important to the pathogenesis of TPI
sgk
.  Here we 
demonstrate that the M80T substitution in TPI
sgk
 reduces its isomerase activity and, based on the 
proximity to one of the TPI catalytic sites, we predict that the reduced catalytic efficiency is a 
result of the mutation’s influence on dimeric catalytic activity. 
To address whether the presence of the enzyme or its catalysis were most important to the 
TPI
sgk
 disease phenotypes in vivo, we developed genomic engineering (GE) of the Drosophila 
TPI locus.  This process establishes an attP ΔTPI founder line, which can be used to modify the 
gene locus using highly efficient attP/attB transgenesis.  We hypothesized that if the presence of 
the enzyme was critical to pathogenesis independent of catalytic activity, then we would be able 
to rescue the disease phenotypes with a catalytically inactive variant of the protein.  Lys12 of 
TPI is a fully conserved catalytic residue previously shown to be required for substrate binding, 
and a mutation to Met completely abrogates catalysis (16,104).  We have generated the attP 
ΔTPI founder line and have used GE to create Drosophila TPI∆cat encoding a catalytically-
inactive TPI.  Here we demonstrate that TPI
∆cat
 genetically complements the longevity and 
behavior of the TPI
sgk
 animal model of TPI deficiency.  Furthermore, catalytically inactive TPI 
complements TPI
sgk
 phenotypes without enhancing its stability or catalysis or reducing the 
associated metabolic stress. 
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2.3 RESULTS 
2.3.1 Recombinant TPI enzyme activity   
Previous studies established that TPI
sgk
 is a recessive loss-of-function mutation characterized by 
reduced TPI levels (85).  Further, it was suggested that TPI
sgk
 retained sufficient activity to 
rescue mutant survival and behavioral phenotypes if overexpressed (85).  Based on these data we 
hypothesized that reduced TPI catalysis was critical to the pathogenesis of TPI deficiency.  To 
investigate this hypothesis further we generated recombinant Drosophila WT (dWT) and TPI
sgk
 
(dM80T) and examined the kinetics of isomerase activity for each (Table 1).  These data 
demonstrate that TPI
sgk
 (dM80T) exhibits a substantial reduction in isomerase activity.  The 
dM80T protein does not significantly change substrate affinity, yet elicits an ~11-fold reduction 
in catalytic activity compared to WT enzyme.  This ultimately resulted in a ~15-fold reduction in 
enzyme efficiency.  Both enzymes displayed typical Michaelis-Menten kinetics (Figure 3). 
 
 
 
Figure 3.  Both Drosophila wild type (dWT) and sugarkill (dM80T) enzymes follow traditional 
Michaelis-Menten kinetics.  Michaelis-Menten nonlinear regression fits are shown, and all enzyme 
concentrations are indicated. 
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Table 2. Kinetic parameters of Drosophila wild type (dWT) and sugarkill (dM80T) triosephosphate 
isomerase enzymes. 
 dWT dM80T 
kcat (GAP) (s
-1
)  1454 ± 163.6 129.6 ± 1.5 
Km (GAP) (mM) 2.8 ± 0.4  3.7 ± 0.5 
kcat/Km (GAP) (s
-1
 M
-1
) 5.2x10
5
 3.5x10
4
 
* ± SEM 
 
To assess the role of the M80 position within TPI function, we analyzed the crystal 
structure of TPI from G. gallus (105) – Drosophila TPI shows 67% identity and 80% functional 
conservation with G. gallus.  This structure was determined in the presence of the transition-state 
analog phosphoglycolohydroxamic acid (PGH), and the homologous methionine (M81) is 
located within TPI’s third loop (residues 63 to 86) (Figure 4A).  This loop coordinates numerous 
interactions within the dimerization interface of TPI including important contacts between M81 
and M13 and N14 of the neighboring subunit (Figure 4B).  These hydrophobic interactions help 
position the third loop, and are aided by hydrogen bonding between residues T74 and E76 (also 
on the third loop), which interact with H95 and R98, respectively.  The sum of these interactions 
is a coordinated network using conserved residues to mediate both hydrophobic and hydrogen-
bonding interactions that ultimately positions both K12 and H95 properly within the active site 
of the enzyme (Figure 4B & 4C). These residues are critical for enzymatic function in TPI 
(106,107) and establish a connection between M80 in Drosophila TPI and reduced catalysis for 
TPI
sgk
. 
Biochemically establishing that TPI
sgk
 still retains catalytic activity supported a catalytic 
explanation of our phenotypic attenuation via TPI
sgk
 transgenic overexpression.  However, a 
rigorous assessment of this hypothesis in vivo would require supplementation of TPI levels 
without modifying its activity.   
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Figure 4.  Positioning of the third loop forms an interaction network connecting the dimerization 
interface to the catalytic pocket.  A) The crystal structure of TPI dimer from Gallus gallus (PDB ID, 1TPH).  
Monomer A of the dimer is rendered as a surface and colored white, while Monomer B (blue) is shown as a 
cartoon with the third loop highlighted in orange.  The position of the transition state analog 
phosphoglycolohydroxamic acid (PGH, green) is indicated within the catalytic pocket.  B) Local environment 
of the third loop.  Colored as before, with residues making important contributions to the dimerization 
interface indicated as sticks.  Van der Waals interactions between M81 and residues M13 and N14 are 
indicated as black dotted lines.  Hydrogen bonds between residues on the distal end of the third loop and 
connecting to the catalytic core are given as green dotted lines.   Residues are numbered based on Gallus 
gallus sequence, and for clarity we are using the TPI numbering standard that accounts for the removal of 
the initiator methionine.  C) An alignment of TPI protein sequences from H. sapien, G. gallus, and D. 
melanogaster.  Protein alignment was performed using the Clustal W method, with H. sapien and G. gallus 
showing 63.5% and 67.3% identity to D. melanogaster.  Residues that mediate TPI dimerization are indicated 
by grey circles. Residues within the hydrogen-bonding network critical for catalysis are indicated (Cyan). The 
position of the sugarkill mutant (M81, red) and its positions within the third loop (orange box) are indicated. 
 28 
2.3.2 Generation of the founder knock-out line by homologous recombination  
To create a catalytically inactive allele of TPI we developed a GE approach for the TPI 
locus.  Homologous recombination (HR) in Drosophila had previously been developed (96,108) 
but recent advances in GE technology have made the process considerably more efficient 
(99,100).  The GE founder line was generated through replacement of the endogenous TPI locus 
using ends-out homologous recombination with a functional attP element (Figure 5A).  TPI is 
located on the third chromosome between CG31029 (centromeric) and AdoR (telomeric).  
Homology arms directing the deletion of the entire TPI locus were PCR amplified from the w
1118
 
wild type genomic DNA and cloned into the pGX-attP targeting vector.  Traditional P-element 
transgenesis was used to obtain pGX-attP insertion on the second chromosome.  HR was induced 
as previously outlined (99).  Approximately four hundred putative positive HR events were 
identified after screening ~ sixty thousand (60,000) animals.  Among the putative positives, three 
positive HR lines were identified and verified using genetic and molecular methods.   
Genetic validation included failure to complement a previously identified TPI null allele, 
TPI
JS10
 (50), and homozygous lethality.  Molecular validation included PCR analyses to confirm 
proper targeting of left and right homology arms using primers directed outside the homology 
arms and within construct elements.  The confirmed founder line was reduced to remove w
mc+
 
using a CRE recombinase and is designated attP ΔTPI (Figure 5B).  The entire attP ΔTPI region 
was sequenced to confirm the correct placement of the GE elements and the integrity of the 
homology arms.  
GE was performed to create TPI
+ 
(attR), TPI
+
-CFP (attR), TPI
M80T
 (attR), TPI
∆cat 
(attR), 
and TPI
∆cat
 -CFP (attR) animals using standard phiC31 site-directed integration followed by 
CRE-mediated reduction to remove w
mc+
 (Figure S2). These animals were molecularly verified 
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using PCR analyses of the attR construct element (Figure 5E) and the locus was sequenced.  
Importantly, GE TPI
+ 
(attR) animals are homozygous viable and behave normally while animals 
bearing the M80T substitution are substantially stress sensitive and exhibit reduced longevity 
(Figure 6).  Animals homozygous for TPI
∆cat 
(attR) are lethal, indicating a necessity for TPI 
catalysis during development. 
 
Figure 5.  Genomic engineering of the TPI locus.  A)  The target gene is replaced by the attP phiC31 
integration site and a white minigene flanked by two loxP sites.  B)  The white minigene is removed by a CRE 
recombinase, leaving only the attP phiC31 integration site and a loxP site.  C)  TPI is cloned into the pGE-attB 
vector and modified, as desired.  The construct is then injected into founder line embryos expressing the 
phiC31 integrase, which initiates specific and directional integration of the contruct into the TPI locus.  D)  
The white minigene and plasmid construct are removed through the expression of CRE recombinase, leaving 
only an attR and a loxP site.   E)  Molecular analysis reveals the addition of an attR site 5’ of the reconstituted 
TPI gene. 
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Figure 6.  Genomically engineered TPI
sgk
 displays aberrant behavior and reduced longevity.  A)   
Genomically engineered TPI
+
 (GE-WT) displays normal behavior, while the genomically engineered TPI
sgk
 
(GE-sgk) displays marked mechanical stress sensitivity.  B)  GE-sgk exhibits reduced longevity compared to 
GE-WT.  n > 20 for all lifespans and behavior.  A Student’s t test was used to assess behavioral differences 
between genotypes, and a Log-rank (Mantel-Cox) Test was used to assess lifespans.  *** indicates p < 0.0001 
compared to GE-WT.  Error bars indicate ± s.e.m.  Both genomically engineered alleles were assessed over 
TPI
null
. 
2.3.3 Animal behavior and longevity 
To test whether TPI – independent of catalytic activity – is crucial to disease 
pathogenesis, TPI
sgk
/TPI
+
, TPI
sgk
/TPI
sgk
, TPI
sgk
/TPI
null
, and TPI
sgk
/TPI
∆cat
 animals were collected 
and aged at 25°C.  TPI
null
 is a null allele owing to a 1.6 kb deletion, therefore TPI
sgk
/TPI
null
 
animals represent approximately the amount of TPI produced by one allele of TPI
sgk
.  For the 
purposes of this study, contrasting TPI
sgk
/TPI
null
 with TPI
sgk
/TPI
∆cat
 provides the most 
informative comparison, as each animal population contains one catalytically active TPI allele.     
Male and female animals were housed in vials of 10-20 individuals and examined for 
mechanical- and temperature-dependent locomotor defects on day three and twenty.  Time to 
recovery and time to paralysis were measured in each assay. While TPI
sgk
/TPI
+
 shows no sign of 
paralysis or seizures upon mechanical stress, TPI
sgk
/TPI
sgk
 and TPI
sgk
/TPI
null
 exhibit a clear delay 
in recovery (Figure 7A).  In contrast, TPI
sgk
/TPI
∆cat
 animals display no signs of stress sensitivity 
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(Figure 7A).  Previously, we have shown that TPI
sgk
 phenotypes are progressive in nature 
(50,85).  We measured these behaviors at two time points, day 3 and day 20 to reveal whether 
TPI
∆cat
 fully complements the TPI
sgk
 phenotypes or simply delays their onset.  The catalytically 
inactive enzyme was shown to rescue mechanical stress sensitivity at both time points indicating 
that the TPI
∆cat
 allele does not simply delay the progression of the disease phenotype (Figure 
7A). 
 
Figure 7.  The catalytically inactive TPI
∆cat
 rescues behavioral and longevity phenotypes in TPI
sgk
.  A)  
TPI
∆cat
 complements TPI
sgk
 mechanical stress sensitivity at both day 3 and day 20.  B)  TPI
∆cat
 expression 
complements TPI
sgk
 thermal stress sensitivity, again at both day 3 and day 20.  † indicates TPIsgk/TPI+ and 
TPI
sgk
/TPI
∆cat
 animals did not paralyze.  C)  TPI
∆cat
 complements the longevity defect of TPI
sgk
.  ** indicates p 
< 0.01 and *** p < 0.001 relative to TPI
+
/TPI
+
.  n > 15 per genotype for all behavioral assays, and n > 150 per 
genotype for all lifespans.  Error bars indicate ± s.e.m. 
 
Thermal stress sensitivity of the animals was also evaluated to test the possibility of 
pathogenic divergence (Figure 7B).  Here, TPI
sgk
/TPI
+
 shows no signs of paralysis or seizures 
upon thermal stress, while TPI
sgk
/TPI
sgk
 and TPI
sgk
/TPI
null 
animals show distinct paralytic 
phenotypes initiated at ~240 sec. and ~90 sec. respectively (Figure 7B).  In contrast, animals 
expressing the catalytically inactive allele TPI
sgk
/TPI
∆cat
 displayed no signs of paralysis after 
thermal stress induction (Figure 7B).  Again, we measured these behaviors at two time points, 
day 3 and day 20, and expression of the catalytically inactive enzyme was shown to rescue 
thermal stress sensitivity at both time points (Figure 7B). 
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To test whether genetic complementation extended to longevity we assessed lifespans as 
previously described (109). TPI
sgk
 animals exhibit a marked reduction in median longevity that 
was also complemented with the catalytically inactive TPI
∆cat
 allele (Figure 7C).  Finally, all 
genotypes eclosed at Mendelian rates suggesting the absence of developmental deficits and that 
the behavior of the adult population is representative of the genotype as a whole. 
2.3.4 TPIsgk animal bioenergetics and lysate enzyme activity 
Genetic complementation with TPI
∆cat
 could indicate a previously unidentified non-isomerase 
function of the enzyme or it could result from a restoration of isomerase activity by a number of 
possible mechanisms.  Thus, we examined whether TPI
∆cat
 provided genetic complementation 
through a restoration of enzyme isomerase activity. TPI enzyme activity was robust in both 
TPI
+
/TPI
+
 and TPI
sgk
/TPI
+
 lysates yet markedly reduced in TPI
sgk
/TPI
sgk
 and TPI
sgk
/TPI
null
 
animals (Figure 8A). Most importantly, TPI
sgk
/TPI
∆cat
 animals exhibit levels of isomerase 
activity similar to TPI
sgk
/TPI
sgk
 and TPI
sgk
/TPI
null
 animals demonstrating that the genetic 
complementation is independent of isomerase activity (Figure 8A). 
 
 
Figure 8.  TPI
∆cat
 fails to rescue animal bioenergetics and TPI enzyme activity.  A)  TPI
sgk
 exhibits 
little activity in animal lysates.  Additionally, complementing TPI
sgk
 with TPI
∆cat
 does not rescue its activity in 
vivo.  Inset: A between TPI
sgk
/TPI
null
 and TPI
sgk
/TPI
∆cat
 lysate kinetics reveals low activity levels in both 
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lysates.  Note the axes are maintained but units have been changed.  B)  TPI
sgk
/TPI
null
 animals and 
TPI
sgk
/TPI
∆cat
 animals both showed reduced ratios of P-arg/arginine indicating bioenergetic stress.  *** 
indicates p < 0.001 relative to WT.  Error bars indicate ± s.e.m. 
 
The dramatic reduction in lysate isomerase activity suggested that pathogenesis of TPI
sgk
 
neurological phenotypes could be unrelated to animal metabolic stress.  Previous studies 
measuring ATP levels in this same mutant have failed to detect a significant change (64).  To 
further evaluate the relationship between metabolism and TPI deficiency behavioral and 
longevity phenotypes we measured phospho-arginine [P-arg] to arginine [arg] ratios as 
previously described (110), as this is an extremely sensitive assay of Drosophila bioenergetic 
status (76).  [P-arg]/[arg] ratios in TPI
sgk
 mutant animals were depressed compared to wild type, 
consistent with a strong loss-of-function mutation in glycolysis (Figure 8B).  This represents a 
reduction in the available pool of [P-arg] normalized to the total [arg] available, and suggests that 
the animals are utilizing this pool at a higher rate to buffer their ATP levels, similar to how 
mammals utilize phosphocreatine (76).  Importantly, TPI
sgk
/TPI
∆cat
 animals exhibiting low levels 
of catalytic activity also showed a similar depression in their [P-arg]/[arg] ratios compared to 
wild type animals (Figure 8B).  These data indicate that TPI
∆cat
 rescues TPI
sgk
 phenotypes by a 
mechanism independent of TPI’s well-established role in cellular bioenergetics, and may provide 
an explanation as to the absence of an association between enzyme catalysis and neurological 
complications in human patients. 
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2.3.5 TPIsgk and TPI∆cat protein levels 
The capacity of a catalytically inactive allele of TPI to genetically complement all 
behavioral and longevity phenotypes independent of isomerase activity and animal metabolism 
strongly supports the conclusion that TPI
sgk
 phenotypes are due to a change in total TPI protein 
levels, not a reduction in TPI catalytic capacity.  To determine whether the catalytically inactive 
TPI rescues total TPI levels, we immunoblotted for the presence of TPI with or without a cyan 
fluorescent protein (CFP) tag; the use of the tag allowed us to discriminate between protein 
isoforms.  Figure 10 shows that the addition of this C-terminal CFP does not influence the 
capacity of TPI
∆cat
 to rescue the TPI
sgk
 phenotypes.   TPI
sgk
 display reduced TPI protein levels in 
vivo (85,86), and TPI levels were further reduced when TPI
sgk
 was paired with the null allele, 
TPI
null
 (Figure 9A,C).  Interestingly, complementing TPI
sgk
 with the catalytically inactive allele 
TPI
∆cat
 rescues the total TPI protein levels to that seen in the aphenotypic TPI
+
/TPI
+
 wild type 
homozygotes.  Observing TPI
∆cat -CFP
 and TPI
sgk
 independently, it can be seen that TPI
∆cat -CFP
 
fails to rescue TPI
sgk
 levels (Figures 9A,C) and, conversely, mutant TPI
sgk
 protein does not 
induce the degradation of TPI
∆cat -CFP
 (Figures 9B,C). 
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Figure 9.  TPI
∆cat
 expression does not prevent the degradation of TPI
sgk
.  A)  Shown is a quantification 
of the levels of untagged TPI.  TPI
sgk
 complemented with TPI
∆cat
 shows elevated levels of total TPI similar to 
WT.  Additionally, TPI
sgk
/TPI
null
  have similar levels of TPI compared to TPI
sgk
/TPI
∆cat -CFP
.  ** indicates p < 
0.01 and *** p < 0.001 compared to WT.  Further, ns indicates no significant change compared to 
TPI
sgk
/TPI
null
.  n = 4.  B)  TPI
sgk
 does not induce the degradation of TPI
∆cat-CFP
.  Shown is a quantification and 
comparison of the levels of TPI
∆cat-CFP
 (C).  Student’s T test was used to compare the two groups and found no 
significant difference (ns).  n = 4.  C)  Shown is a representative blot from which Figures 9A and 9B were 
quantified.  The loading control used was ATPalpha (Na,K-ATPase).  Error bars indicate ± s.e.m. 
 
 
Figure 10.  The addition of the C-terminal CFP to TPI
∆cat
 does not affect its capacity to genetically 
complement TPI
sgk
.  A) mechanical stress sensitivity or B) thermal stress sensitivity.  Mechanical stress 
sensitivity was assessed on Day 1 and thermal stress sensitivity was assessed on Day 5.  n > 15.  † indicates 
animals did not paralyze.  A One-way ANOVA was performed to assess variance and data sets were 
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compared using Tukey’s post-hoc analysis.  *** indicates that p < 0.001 and ns indicates no significant 
difference, both compared to WT.  Error bars indicate ± s.e.m. 
 
The inability of TPI
∆cat -CFP
 to modulate TPI
sgk
 levels suggests that any phenotypic rescue 
is likely being performed by the catalytically inactive isoform, and not merely increasing the 
presence of a still catalytically active TPI
sgk
.  Secondly, it is of particular interest that TPI
sgk
 does 
not significantly influence the levels of TPI
∆cat -CFP
.  These results suggest three possible 
interpretations: i) TPI
sgk
 is degraded prior to but stable upon heterodimerization, ii) TPI
sgk
 
monomers are selectively degraded from heterodimer complexes, or iii) that TPI
sgk
 and TPI
∆cat
 
never exist as a heterodimer.  Taken together, these results confirm that TPI
∆cat
 complements the 
TPI
sgk
 phenotypes independent of isomerase activity demonstrating a non-catalytic function of 
TPI critical to the pathogenesis and severity of TPI deficiency.  
2.4 DISCUSSION 
The sugarkill model of TPI deficiency used in these experiments is characterized by 
reduced catalysis and protein stability, characteristics found in several of the more toxic human 
TPI alleles (57,102,111).   Similarly, the M80T mutation recapitulates the neurological 
dysfunction and toxicity exhibited in many of the human patients.  Using the Drosophila model 
we have genomically engineered (GE) the TPI locus to make targeted in vivo modifications to 
the endogenous gene.  GE allows us to study TPI manipulations under endogenous regulatory 
control, allowing rigorous experiments that would not be feasible with traditional transgenic 
approaches (101,112,113).  The power of GE is born in its capacity to study a gene’s function in 
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vivo while reducing artifacts due to transgenic over expression and miss expression.  Previous 
studies analyzing TPI deficiency have primarily utilized human patient erythrocytes, yeast and 
mammalian cellular expression systems.  Although these experimental paradigms are valuable, 
they do not provide the elegant endogenous genetic control of GE and preclude the examination 
of in vivo phenotypes such as behavior and longevity. 
We initiated this study asking whether the presence of the enzyme or its catalytic activity 
was most important to the pathogenesis of our mutant.  Our experiments assessing enzyme 
activity identified that the M80T substitution in TPI
sgk
 resulted in a ~15-fold reduction in enzyme 
efficiency (Table 1).  This reduction in catalytic activity was more severe than those reported in 
two human mutations (63,114), but was not nearly as severe as those modifying critical catalytic 
components (115-118).  An analysis of the TPI enzyme structure taken from G. gallus suggested 
that this mutation might affect isomerase activity through its proximity to several catalytic 
residues (Figure 4).  These results initially supported a catalytic source of disease pathogenesis, 
but further experimentation revealed the capacity for an isomerase-inactive isoform of TPI to 
genetically complement all behavioral and longevity phenotypes of TPI
sgk
. The capacity of a 
catalytically inactive TPI to rescue a severe variant of TPI deficiency independent of any 
changes in isomerase activity was striking.  Thus far most research on TPI deficiency has 
focused on two core principles: i) Inhibited TPI activity would slow glycolysis, and ii) Inhibition 
of TPI would lead to a buildup of excess DHAP and henceforth toxic advanced glycation end-
products (AGEs) (48).  Here we have shown that the addition of an isomerase-dead isoform of 
TPI rescues all behavior independent of catalysis, making it unlikely that AGEs are playing a 
significant role in the genesis of our behavioral or longevity phenotypes. Our findings of genetic 
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complementation independent of an effect on TPI
sgk
 isomerase activity or animal bioenergetics 
suggest a non-metabolic source of TPI deficiency pathogenesis. 
Although glycolytic enzymes are not often thought of as important players in non-
metabolic cellular mechanisms, work spanning the past two decades has clearly outlined vital 
non-metabolic roles for some of these ancient proteins.  Glycolytic enzymes have been described 
in a multitude of different non-catalytic roles, including assistance in assembly and function of 
the vacuolar-type proton-ATPase by aldolase (119,120), inhibition of apoptosis through the 
modulation of Bax, Bak and Bad by hexokinase (121,122), transcriptional regulation of the 
histone H2B gene during cell cycle progression by glyceraldehyde 3-phosphate dehydrogenase 
(123), and the induction of cell motility and invasion through the secretion and binding of 
glucose-6-phosphate isomerase to the autocrine motility factor receptor gp78 (124).  Based on 
this diversity of functions, it is clear that there is the potential for glycolytic enzymes to perform 
functions dramatically independent from their roles in glycolysis.  Our findings are particularly 
relevant as TPI is one of the primary targets of nitrotyrosination in Alzheimer’s disease and is 
sequestered in the neurofibrillary tangles in patient brains (125,126).  Sequestration such as this 
could inhibit a critical non-catalytic function of TPI, further contributing to the neurological 
dysfunction known to be associated with tau aggregation and toxic amyloid beta. 
Recently TPI has been identified as a target of cyclin dependant kinase 2 (cdk2) (127) 
and arginine methyltransferase 5 (PRMT5) (128).  Together, these studies conclude that TPI is 
more highly regulated than previously appreciated.  Furthermore, it was noted that TPI protein 
levels could be modulated via methylation (128).  These results portend the enticing possibility 
that TPI protein levels are regulated in a cell-cycle dependent manner, and that its relationship to 
the cell cycle could be perturbed in TPI deficient patients experiencing neurological symptoms.  
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Indeed, a relationship has already been well-established between cell cycle misregulation and 
neurodegeneration (reviewed in 129), and inappropriate regulation of the cell cycle has been 
described in Alzheimer’s Disease (130).  It is clear that further work is needed to define the 
biological role of post-translational modifications of TPI, and the role of TPI as either a direct or 
indirect component of the cell cycle. 
In conclusion, our data demonstrate the capacity of a catalytically inactive TPI enzyme to 
genetically complement TPI deficiency behavioral phenotypes independent of changes in 
bioenergetics or enzyme catalysis. The identification of an isomerase-independent function for 
this critical protein opens up new avenues of investigation that will prove critical to 
understanding TPI’s role in maintaining normal neural function and TPI deficiency pathogenesis.  
2.5 MATERIALS AND METHODS 
2.5.1 Animal Strains 
The w*; P[GawB] 477w-; TM2/TM6B, Tb
1
 and y,w/Y, hs-hid; hs-FLP, hs-I-SceI/CyO, hs-hid; 
stocks were obtained from Dr. Yang Hong.  TPI
sgk
 is a missense mutation resulting in a Met-to-
Thr change at position 80, while TPI
null
 is a null allele owing to a 1.6 kb deletion of two of the 
three constitutively expressed exons of the TPI locus (50).  This numbering uses the established 
nomenclature for TPI mutations, assuming the start methionine is removed following translation 
(45); and for consistency all residue numbering in this study uses the same convention.  The Cre 
recombinase stock was used to reduce the locus following homologous recombination and 
phiC31 integration.  The strain used, y
1
 w
67c23
 P[y[+mDint2]=Crey]1b; D
*
/TM3, Sb
1
, was 
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obtained from the Bloomington Drosophila Stock Center (Bloomington, IN, USA).  Care was 
taken to ensure all animal populations assessed were approximately equivalent mixtures of males 
and females, with the exception of the TPI
sgk
/TPI
null
 day 20 behavioral tests – in this genotype 
males died noticeably faster than females and as a result this small population of survivors 
consisted mostly of female animals.  
2.5.2 Genomic Engineering  
We performed the TPI GE similar to previously published methods (99,100).  Briefly, ~ 2.6 kb 
homology arms were generated by PCR amplification to areas 5’ and 3’ of the TPI locus.  These 
homology arms were inserted into the pGX-attB vector (99) and transferred onto the second 
chromosome of w
1118
 animals using traditional P-element transgenesis.  Ends-out homologous 
recombination was performed and founder lines were molecularly verified.  The wild type TPI 
locus was cloned into the pGE-attB vector via PCR and verified by sequencing.  Founder lines 
were mated to vasa-phiC31
ZH-2A
 animals expressing the integrase on the X chromosome and their 
progeny injected with pGE-attBTPI
+
, pGE-attBTPI
+
-CFP, pGE-attBTPI
M80T
, pGE-attBTPI
∆cat
, 
or pGE-attBTPI
∆cat
 -CFP constructs.  Integration events between attP and attB elements produce 
an attL and attR and reconstitute the target locus.  Such events were identified based on the 
presence of the w
+
 phenotype and verified molecularly.   
2.5.3 Mutagenesis 
Site directed mutagenesis was performed using the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA).  Mutagenesis primers were 
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generated (Integrated DNA Technologies, Coralville, IA, USA) to introduce a Lys-to-Met codon 
change affecting position 11 and a Met-to-Thr codon change affecting position 80 of the protein.  
Mutagenesis was performed on the pGE-attBTPI
+
 plasmid and confirmed by sequencing. 
2.5.4 Drosophila TPI purification 
The coding sequence for Drosophila TPI was cloned into the bacterial expression vector pLC3 
using standard techniques.  The resulting plasmid directs expression of TPI containing N-
terminal His6- and MBP-tags, both of which can be removed with TEV protease.  TPI protein 
was expressed in BL21(DE3) Codon-Plus (RILP) E. coli (Agilent Technologies) grown in ZY 
auto-induction media (131) at room temperature for 24-30 hours.  Cells were harvested by 
centrifugation, lysed via homogenization in 25 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 5 
mM Imidazole, 1 mM β-mercaptoethanol and cleared by centrifugation at 30,000 x g.  TPI was 
purified by nickel affinity chromatography followed by overnight TEV protease treatment to 
cleave the His6-MBP tag from TPI.  A second round of nickel affinity purification was 
performed to separate the His6-MBP and TEV protease.  TPI protein was further purified using 
cation-exchange chromatography (HiTrap-QP) followed by gel filtration (Sephacryl S-200, GE 
Healthcare, Little Chalfont, England, UK).  Peak fractions were concentrated to 4-8 mg/ml in 20 
mM Tris pH 8.8, 25 mM NaCl, 2.0% glycerol and 1 mM β-mercaptoethanol using a Vivaspin 
concentrator (GE Healthcare).  The purity was >99% as verified by SDS-PAGE.  Expression and 
purification of the Drosophila TPI M80T sgk mutant was performed as described above. 
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2.5.5 Enzyme Assays 
Isomerase activity was determined using an NADH-linked assay as previously detailed (132).  
TPI activity was measured with three different enzyme concentrations of both purified 
Drosophila WT and M80T enzyme.  Initial velocity of the enzyme was calculated over a GAP 
(Sigma-Aldrich, St. Louis, MO, USA) range of 0.94-5.64 mM.  All kinetic measurements were 
performed three times in triplicate by monitoring the absorbance of NADH at 340 nm in a 
SpectraMax Plus 384 microplate reader (Molecular Devices, Sunnyvale, CA, USA).  The assay 
was performed using 80 µl mixtures containing varied GAP and enzyme concentrations, 0.42 
mM NADH (Sigma-Aldrich), and 1 unit glycerol-3-phosphate dehydrogenase (Sigma-Aldrich) 
in 100 mM triethanolamine (TEA), pH 7.6.  Enzyme activity curves were normalized to 
reactions performed without GAP.  Enzyme kinetics were determined by assessing initial 
velocities taken during the linear phase of each reaction, and the data were fit to the Michaelis-
Menten equation using nonlinear regression in Graphpad Prism 5.0b (GraphPad Software, La 
Jolla, CA, USA). 
For lysate assays, animals were collected and aged to day 3 at 25°C and frozen in liquid 
nitrogen.  Bodies lacking the head and appendages (abdomen and thorax) were isolated after 
vigorous mechanical shaking of the frozen animals.  Tissues lacking eye pigments were used to 
reduce background absorbance.  The bodies were homogenized in 0.75 ml of 1X PBS (2.7 mM 
KCl, 137 mM NaCl, 2 mM NaH2PO4, 10 mM Na2HPO4 pH 7.4) with protease inhibitors 
Leupeptin 1:1000 (Acros Organics, Geel, Belgium), Pepstatin 1:1000 (Sigma-Aldrich), PMSF 
1:100 (Pierce, Rockford, IL, USA).  The homogenates were ice bath-sonicated for 10 min. then 
centrifuged at 4°C for 5 min. at 5,000 x g to remove exoskeletal debris.  Lysates were diluted to 
1 µg/µl in 100 mM TEA, pH 7.6 + inhibitors and TPI enzyme activity was assessed using a 
 43 
linked-enzyme assay, similar to that outlined above.  The assay was performed using 80 µl 
mixtures containing 0.47 mM GAP, 0.42 mM NADH, 1 unit glycerol-3-phosphate 
dehydrogenase and 30 µg of lysate protein in 100 mM TEA, pH 7.6.  Enzyme activity curves 
were performed three times in triplicate and normalized to reactions performed without GAP.  A 
One-way ANOVA was performed to assess variance and data sets were compared using Tukey’s 
post-hoc analysis.   
2.5.6 Behavioral Testing and Lifespan Analysis 
Mechanical stress sensitivity was determined by vortexing the animals in a standard media vial 
for 20 seconds and measuring time to recovery, similar to (133).  Thermal stress sensitivity was 
assessed by acutely shifting animals to 38°C and measuring time to paralysis, as previously 
described (65,109).  All behavioral responses were capped at 600 seconds.  Testing days were 
selected based on previous experience with TPI deficiency progression in Drosophila (50).  
Animal lifespans were performed at 25°C as previously described (109).  Two-way ANOVAs 
were performed with Bonferroni’s post test to compare genotype behavior over time, and 
lifespans were compared with Log-rank (Mantel-Cox) survival tests.   
2.5.7 HPLC Phosphoarginine Assay 
Three sets of 25 animals per genotype were collected and aged to day 3 at 25°C and frozen in 
liquid nitrogen.  The animals were homogenized in 200 µl 0.6 M perchloric acid and neutralized 
with 25 µl of 2 M potassium carbonate.  The lysates were then centrifuged at 12,000 x g for 10 
min. at 4°C and the supernatant filtered through a PVDF 0.45 µm spin column (National 
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Scientific, Rockwood, TN, USA) at 12,000 x g for 5 min. at 4°C as previously described (76).  
These extracts were injected onto a Phenomenex Luna 5µm NH2 250 x 4.6 mm column 
(Torrance, CA, USA) using a Shimadzu high performance liquid chromatography (HPLC) 
system (Kyoto, Japan) and separated with a 95:5 20 mM KH2PO4 pH 2.6: acetonitrile linear 
mobile phase at a flow rate of 0.6 ml/min.  Arginine (Acros Organics) and phospho-arginine (P-
arg) standards were detected at 205 nm, and all samples were measured in triplicate (76).  
Phosphoarginine standards were generated as previously described (134).  Peak analysis was 
performed using EZStart 7.3 software (Shimadzu), and P-arg levels were normalized to total 
arginine and compared across genotypes.  Retention times for arginine and phospho-arginine 
were 3.7min and 5.4min respectively.  A One-way ANOVA was performed to assess variance 
and data sets were compared using Tukey’s post-hoc analysis.   
2.5.8 Immunoblots 
Animals were collected and aged at 29°C.  After 24hrs., ten fly heads were collected in triplicate 
from each genotype and processed as outlined previously (86).  Briefly, the fly heads were 
ground by pestle in 80µl 2× SDS–PAGE sample buffer (4% SDS, 4% β-mercaptoethanol, 
130mM Tris–HCl pH 6.8, 20% glycerol) and spun for 5min. at 5,000 x g to pellet the 
exoskeleton. Proteins were resolved by SDS–PAGE and transferred onto PVDF membrane.  
Following treatment in 1% milk PBST, the blots were incubated with anti-TPI (1:5000; rabbit 
polyclonal FL-249; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-ATPalpha 
(1:10,000; mouse monoclonal alpha5; Developmental Studies Hybridoma Bank, Iowa City, IA, 
USA).  The blots were washed in PBST, incubated in the appropriate HRP-conjugated secondary 
antibody, and developed using ECL (Pierce).  Densitometric analyses of the scanned films were 
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performed digitally using ImageJ software available from the National Institutes of Health.  A 
One-way ANOVA was performed to assess variance of TPI levels and data sets were compared 
using Tukey’s post-hoc analysis. 
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3.0  CHANGES IN TRIOSEPHOSPHATE ISOMERASE DIMER INTERFACE 
MORPHOLOGY ELICIT BEHAVIORAL DYSFUNCTION BY INHIBITING 
SYNAPTIC VESICLE RECYCLING 
3.1 ABSTRACT 
Triosephosphate isomerase (TPI) is a homodimeric non-linear glycolytic enzyme, which 
enhances glycolytic efficiency yet is not required for the production of pyruvate.  Dysfunction 
within TPI elicits a disease called TPI deficiency, and this pathology currently lacks any 
treatments.  TPI Deficiency is unique among other glycolytic enzymopathies for its severe 
patient neurological dysfunction and early death.  Previous studies have detailed structural and 
catalytic changes elicited by disease-associated TPI substitutions, but the pathophysiology of this 
disease has never been examined.  In this study, in vitro experiments demonstrate that a 
previously identified toxic Drosophila TPI
M80T
 allele is characterized by a defect in enzyme 
dimerization.  Using the Drosophila genomic engineering system we generated several novel 
TPI alleles which further support the conclusion that changes at the dimer interface are sufficient 
to elicit TPI deficiency.  Genetic complementation and behavioral rescue conclusively establish 
that TPI activity is not predictive of disease presence or severity.  However, examination of a 
severe TPI allele demonstrated that the neurological phenotypes associated with TPI Deficiency 
are caused by impaired vesicle recycling at the synapse.  It is not currently understood why TPI 
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Deficiency is unique among other glycolytic enzymopathies in these patient symptoms, though 
our findings suggest a critical subcellular locale deficient in glycolytic ATP.  Clinically, these 
findings are the first to inform targeted therapeutic strategies for patients suffering from TPI 
Deficiency.   
3.2 INTRODUCTION 
Triosephosphate isomerase (TPI) is a glycolytic enzyme that converts dihydroxyacetone 
phosphate (DHAP) into glyceraldehyde-3 phosphate (GAP).  TPI is a non-linear member of the 
glycolytic pathway, enhancing the efficiency of the catabolic process, and mutations within 
coding region of TPI lead to a disease known as TPI deficiency (26).  TPI deficiency is one of 
the few glycolytic diseases associated with neurological dysfunction, and by far the most severe 
(48).  Previously, a M80T substitution in Drosophila TPI (TPI
M80T
) was identified which elicited 
mechanical- and thermal-stress dependent paralysis (50,64).  Both of these behavioral 
phenotypes have been independently established as hallmarks of neurological dysfunction, and 
each has been used in forward genetic screens to identify novel components of neuronal 
transmission (66,68,69).  To this end, the TPI
M80T
 allele was identified in such a screen (65), and 
the protein was found to be prematurely degraded with reduced catalytic activity (1,85).  This 
reduction in catalytic activity was shown to inhibit glycolytic flux as well as induce metabolic 
stress (1,50).  Subsequent studies demonstrated that the M80T point mutation could be 
complemented by the addition of a catalytically inactive TPI without increasing lysate isomerase 
activity or alleviating metabolic stress (1).  These results were in agreement with observations 
made from patient tissue samples, wherein no changes in ATP were identified (57) and 
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concluded that the behavioral dysfunction associated with Drosophila TPI deficiency was not a 
function of metabolic stress, but instead a result of either a depletion of cellular TPI or a change 
in its protein conformation. 
The results of the present study extend this work and suggest that conformational changes 
of the TPI dimer interface are sufficient to cause Drosophila TPI deficiency.  Indeed, an 
alteration of the dimer interface was previously identified in the most prevalent human disease-
associated TPI mutation (63).  We purified and assessed the physical characteristics of TPI
M80T
, 
identifying a change in protein dimerization.  These results were further supported when 
independent mutations at the TPI dimer interface phenocopied the behavioral dysfunction seen in 
the TPI
M80T
 allele.  A previous study established that TPI
M80T
 could be complemented with a 
catalytically inactive TPI allele, and complementation analyses with the new dimer mutant 
alleles support the conclusion that an improperly formed dimer interface is a far greater 
determinant of behavioral dysfunction than enzyme catalysis.  Further, our experiments establish 
that Drosophila TPI deficiency results in an impairment of synaptic vesicle recycling, which we 
believe are the source of neurological dysfunction in both our Drosophila model and the human 
condition.  A recent study quantifying the ATP production and consumption at the synapse 
established that activity-driven glycolysis was the most critical source of ATP in the synapse 
(135).  Additional analyses of activity-dependant ATP consumption demonstrated that vesicle 
recycling was the largest consumer of ATP in the synapse (135).  These observations suggest 
that our TPI dimer mutations may elicit a local depletion of ATP due to impaired synaptic 
glycolytic flux.  Collectively, these data conclude that Drosophila TPI deficiency is not elicited 
through a general metabolic defect, and suggests that the neurological dysfunction is elicited by 
changes in the dimer interface likely coordinating localization of synaptic isomerase activity.   
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3.3 RESULTS 
3.3.1 RNAi knockdown of WT TPI 
Our previous results suggested that TPI deficiency neurological and longevity phenotypes were 
not a result of metabolic stress.  We found that the severe longevity and behavioral phenotypes 
elicited through the M80T mutation could be complemented through the addition of a stable, 
catalytically inactive isoform of TPI.  These results suggested one of two possibilities through 
which M80T elicited its disease phenotypes: i) that the depletion of cellular TPI was sufficient to 
elicit disease phenotypes, or that ii) M80T generated a conformational change in TPI which 
could be rescued through the addition of a properly folded yet catalytically inactive isoform.  To 
assess the first possibility, we employed the GAL4-UAS expression system to knock down wild 
type (WT) TPI using a UAS-RNAi line directed toward dTPI (Drosophila TPI) messenger RNA 
(mRNA) (136).  These lines were driven by an actin-GAL4, UAS-GAL4 superexpressor to 
obtain a dramatic reduction of TPI in all tissues. 
 
 
Figure 11.  RNAi knockdown of TPI
+
 fails to recapitulate TPI
M80T
 phenotypes.  TPI transcript levels 
were knocked down ubiquitously and confirmed in thorax (A) and head (B) tissues (n≥3).  Knockdown 
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animals failed to display typical mechanical-stress dependent paralysis (C) at Day 5 aged at 25°C (n≥15).  ns 
indicates no significance, ** p<0.01, and *** p<0.001 relative to +/+. 
 
Using UAS-RNAi in conjunction with the superexpressor GAL4, we found that w;actin-
GAL4,UAS-GAL4/+;UAS-RNAi
TPI
/+  animals exhibited a dramatic reduction in TPI protein 
levels similar to that seen in head and thorax tissue from w;;TPI
M80T
 homozygotes [Figure 
11A,B].  Head and body tissues were assessed separately to ensure equivalent knockdown in 
both tissues.  Next, we examined animal behavior in these knockdown populations to determine 
whether depletion of cellular TPI was sufficient to elicit TPI deficiency pathology.  Mechanical 
stress responses were used to measure behavioral dysfunction.  Behavioral characterization of 
these knockdown animals demonstrated no abnormal mechanical- or thermal-stress dependent 
responses akin to those seen in the TPI
M80T
 model [Figure 11C].  The only behavioral 
abnormality noted was an observation of hypoactivity at elevated temperatures, with the 
knockdown animals consistently dwelling near the bottom of the vial relative to their TPI
+
 and 
undriven UAS controls [data not shown].  
3.3.2 In vitro physical characterization of M80T 
These knockdown data suggested a significant depletion of cellular TPI is not sufficient to elicit 
TPI deficiency neurological dysfunction.  This left us to explore the possibility that M80T 
elicited a conformational change in TPI leading to a loss-of-function unrelated to general 
metabolism.  Numerous misfolding events could be hypothesized to occur as a function of the 
M80T substitution, among them alterations of dimerization (62,63) and aggregation (126).  To 
examine the structure of M80T in vitro we attempted to purify Drosophila TPI
M80T 
(dM80T).   
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Previous purification experiments had yielded small amounts of pure Drosophila TPI 
enzyme, but these samples proved unstable, necessitating rapid usage of fresh aliquots of 
purified enzyme for the characterization of kinetic properties (1).  Indeed, even Drosophila TPI
+
 
(dWT) was aggregation prone at high concentrations, making it difficult to conduct physical 
characterization of the protein in vitro.  Conversely, purified human TPI (hTPI) was well-
behaved.  Therefore, in order to physically characterize TPI we were forced to work with human 
protein in vitro.  To validate this approach we generated human WT (hTPI
+
) and human M80T 
(hTPI
M80T
) TPI alleles in the Drosophila gene locus using our genomic engineering (GE) system 
(1).  We found that hTPI
M80T
 was able to recapitulate the disease phenotypes observed in 
Drosophila protein (dTPI) [Figure 12].  It was noted that the phenotypes of hTPI
M80T
 were less 
severe than dTPI
M80T
, possibly due to subtle organism-specific changes in the dimer interface 
(137).  However, to prevent xenogenic complications of our behavioral results, we decided to 
work exclusively with the Drosophila protein in vivo for the remainder of our genetic 
experiments.  Confirmation that hTPI
M80T
 pathologically phenocopied dTPI
M80T
 indicated that 
any conformational change elicited by M80T was likely retained in the human protein, making 
us confident that evaluating hTPI in vitro would yield informative results.   
 
 
Figure 12.  hTPI
M80T
 phenocopies the behavioral and longevity effects of dTPI
M80T
.  hTPI
M80T
 elicits a 
significant delay in time to recovery from mechanical stress (A) at Day 3, time to paralysis after thermal 
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stress (B) at Day 4, and longevity (C) compared to hTPI
+, all reared at 25°C.  n≥20 for behavior and n≥70 for 
lifespans.  * indicates p<0.05 and *** p<0.001. 
 
To generally assess potential conformational differences elicited by the M80T 
substitution, we utilized dynamic light scattering (DLS) to examine hWT and hM80T.  We 
hypothesized that any significant conformational changes would likely be reflected by the 
protein’s hydrodynamic radius.  Analyses of 15µM solutions of hWT revealed a hydrodynamic 
radius of 4.3±0.08nm, while hM80T exhibited a significant reduction to 3.3±0.06nm [Figure 
13A].  The linear slope generated by plotting the intensity correlation data suggested the hWT 
sample was largely monodispersed, much like that of the 15µM sample of bovine serum albumin 
[Figure 13B].  This result was contrasted by the non-linear slope generated upon analysis of 
hM80T [Figure 13B], suggesting the possibility of a polydisperse protein population.  
Polydisperse protein populations would qualify the mean hydrodynamic radius, and indicate that 
it may represent a mixed population of proteins in solution.  Polydisperse populations often 
represent sample aggregation, but sample aggregation would be correlated by an increase in the 
predicted mean hydrodynamic radius.  The observed reduction in TPI mean hydrodynamic radius 
could most simply be interpreted as a disruption of the dimer interface resulting in a mixed 
population of monomer and dimer TPI species.   
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Figure 13.  M80T elicits a conformational change in TPI resulting in reduced dimerization.  The 
M80T mutations confers a reduction in mean protein hydrodynamic radius as measured by dynamic light 
scattering (A).  Intensity correlation plots reveal a largely monodisperse WT population and polydisperse 
M80T population (B).  Gel filtration indicates a change in monomer:dimer ratios elicited by M80T (C) with 
relative quantification (inset).  *** indicates p<0.001 
 
We examined the possibility of a dimerization defect by assessing protein size using gel 
filtration chromatography.  We predicted that if the protein was failing to dimerize appropriately 
we would be able to resolve these species independently and quantify their distribution.  A 
standard curve was used to establish column resolution and 15µM samples of hWT and hM80T 
were injected onto the gel filtration column and their migration monitored by UV light at 280nm.  
As shown in Figure 13C, hWT separated into two distinct peaks – one at 24 min. and another at 
27 min.  The elution times indicate that the 24 min. elution correlated with species around 
50kDa, while 27 min. was predicted to be approximately 28kDa; these sizes corroborate with the 
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predicted molecular weight of both monomeric (27kDa) and dimeric (54kDa) hTPI.  Integrating 
the peak areas revealed an 80:20 split in dimer:monomer ratio of hWT [Figure 13C inset].  
Conversely, it is clear to see that the majority of the hM80T sample eluted at 27 min., resulting 
in a 5:95 dimer:monomer split [Figure 13C inset].  These data conclude that the M80T mutation 
elicits a dramatic conformational change in TPI, resulting in a disruption of dimerization.  
Interestingly, the gel filtration results contradict the monodisperse vs. polydisperse observations 
of the DLS experiments; we believe this could be due to dilution effects as the proteins migrated 
over the large gel filtration column. 
3.3.3 TPI dimer interface mutants 
Having established that the M80T mutation alters enzyme dimerization in vitro, we sought to 
assess whether other independent mutations at the dimer interface of TPI were sufficient to elicit 
neuropathology.  Two novel TPI alleles were generated using GE based on previous studies of 
TPI (19): TPI
T74R
, TPI
G75E
.  Upon generating and balancing the new alleles, it was clear that the 
dimer interface mutants were far more toxic than TPI
M80T
.  Test crosses of balanced stocks 
yielded significantly fewer homozygous animals than the 33% predicted by Mendelian rates, and 
unlike TPI
M80T
, these new stocks required maintenance over balancer chromosomes due to their 
poor viability.  These homozygous animals were extremely short-lived [Figure 14C], with 
median lifespans of 2 and 5 days for TPI
T74R
 and TPI
G75E
 respectively. 
To obtain a fair sample size, the poor health of these stocks necessitated the examination 
of behavior on Day 1 and Day 2 while reared at room temperature.  Mechanical- and thermal 
stress-dependent behavioral defects were assessed.  TPI
M80T
 was previously described to exhibit a 
modest phenotype at these time points (50), and these data corroborate our analysis of the GE 
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TPI
M80T
 allele [Figure 14A,B].  In contrast, the dimer interface mutants displayed a more severe 
degree of behavioral dysfunction than that seen in TPI
M80T
 [Figure 14A,B].  These data supported 
our hypothesis that mutations at the dimer interface were sufficient to induce neurological 
dysfunction. 
Lysate isomerase activity was then compared between samples taken from animals 
homozygous for the dimer interface mutants.  First, it was noted that all dimer interface mutants 
exhibited reductions in TPI activity [Figure 14F].  However, a comparison of the TPI
M80T
, 
TPI
T74R
, and TPI
G75E
 lysates revealed a striking observation – the least phenotypically severe 
mutation (TPI
M80T
) was characterized by the lowest isomerase activity.  In comparison, the most 
toxic allele, TPI
T74R
, retained robust activity [Figure 14F].  These data strongly support previous 
observations that TPI activity does not predict the severity or presence of TPI deficiency (1), and 
underlined the conclusion that TPI deficiency is not due to general metabolic stress, but likely a 
change in protein conformation.   
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Figure 14.  Mutations affecting the TPI dimer interface recapitulate M80T phenotypes.  TPI
T74R
 and 
TPI
G75E
 exhibit severe mechanical stress (A) and thermal stress (B) sensitivity, n>30.  Dimer interface 
mutations display severely reduced lifespans (C), n>150.  Both TPI
T74R
 and TPI
G75E
 display reduced protein 
levels (D,E) and reduced lysate isomerase activity (F).  ** indicated p<0.01, *** p<0.001.  # indicates animals 
did not paralyze in 360sec. 
 
Many conformational diseases are elicited through changes in protein structure and 
stability leading to misfolding, then either sequestration and degradation, or aggregation (138).  
First, we examined whether these new dimer interface alleles produced robust levels of TPI 
protein.  We determined TPI levels in our dimer interface mutants as previously (86), and found 
that both TPI
T74R
 and TPI
G75E
 exhibited reduced protein levels in homozygotes [Figure 14D,E]. 
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Figure 15.  TPI dimer interface mutations do not cause aggregation.  Increasing amounts of lysate 
were loaded and show no differences in trapped TPI across all genotypes (A) whereas huntingtin exon1-GFP 
displayed robust retention on the filter (B).  n=2 
 
It has previously been shown that TPI has the capacity to aggregate, and thereby seed the 
aggregation of other proteins such as tau (126).  When measuring protein levels via SDS-PAGE, 
it is important to note that not all aggregate species are SDS soluble, and a reduction in protein 
levels can often be an indication that the aggregates are not passing through the gel matrix.  To 
determine whether the T74R and G75E mutations resulted in protein aggregation we used a dot-
blot filter trap assay to assess retention differences between TPI mutant isoforms, as outlined 
previously (139).  Lysates were collected from homozygous mutants, and from PC12 cells 
expressing GFP-huntingtin-Q97 (GFP htt-Q97) as a positive control.  The results indicate that 
little TPI was trapped on the 200nm filter, yet each sample showed a concentration-dependent 
increase in signal [Figure 15A].  Importantly, no differences were observed in TPI signal 
between any of the dimer interface alleles [Figure 15A].  These data support similar findings 
suggested by sedimentation assays performed on TPI
M80T
 (86).  These experiments lead us to 
conclude that although these dimer interface mutants display reduced protein levels via SDS-
PAGE, this is not due to the insolubility of large aggregates.   
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3.3.4 Complementation with a catalytically inactive TPI allele 
Our previous work suggested that TPI deficiency is a loss-of-function disease caused by either  i) 
the depletion of cellular TPI, or ii) a conformational change which could be rescued through the 
addition of a properly folded yet catalytically open/inactive isoform (1).  Having utilized 
knockdown strategies to examine the necessity of total TPI levels, we sought to confirm the 
capacity of TPI
Δcat
 (Lys-to-Met, position 12) to complement disease-associated TPI alleles.  To 
evaluate whether TPI
Δcat
 is sufficient to support normal behavior and longevity, TPI
+
/TPI
+
, 
TPI
+
/TPI
T74R
, TPI
T74R
/TPI
T74R
, TPI
T74R
/TPI
Δcat
, TPI
+
/TPI
G75E
, TPI
G75E
/TPI
G75E
, and 
TPI
G75E
/TPI
Δcat
 animals were collected and tested as outlined above.  These experiments 
demonstrated that TPI
T74R
 was robustly complemented by TPI
Δcat 
[Figure 16A,B,C], similar to 
the results found with TPI
M80T
 (1).  It should be noted however that this complementation was 
not fully penetrant in that 5 out of the 30 TPI
T74R
/TPI
Δcat
 animals did cease moving near the end 
of the thermal stress assay period [Figure 16B].  Conversely, TPI
G75E
 displayed modest 
behavioral complementation and attenuation of its toxicity, decreasing the penetrance of the 
thermal stress sensitivity to 20 out of 30 animals and extending the median lifespan of the 
TPI
G75E
 mutants from 5 to 21 days [Figure 16D,E,F].  It should be noted that neither of these 
dimer interface mutants elicited dominant negative effects within the TPI
+
 heterozygotes; to the 
contrary, TPI
T74R
 and TPI
G75E
 promoted a significant increase in animal health, extending the 
median 48 day TPI
+
/TPI
+
 lifespans to 77 and 71 days respectively [Figure 16C,F].  Experiments 
assessing TPI activity in these animal lysates revealed no link between isomerase activity and 
disease presence or severity.  Although TPI
T74R
, TPI
G75E
, and TPI
M80T
 exhibit reduced isomerase 
activity, complementation with TPI
Δcat
 occurred without increasing lysate TPI activity, and in all 
but one case significantly reduced it [Figure 17A,B].  The best illustration of this isomerase-
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phenotype disparity can be seen when comparing the activity of TPI
G75E
 with TPI
M80T
/TPI
Δcat
.  
The TPI
M80T
/TPI
Δcat
 animals exhibit normal behavior and longevity (1) yet display substantially 
less isomerase activity than the severely toxic allele, TPI
G75E 
[Figure 17B]. 
 
Figure 16.  A catalytically inactive allele is not sufficient for normal behavior and longevity.  TPI
∆cat
 
complements TPI
T74R
 mechanical (A) and thermal stress (B) sensitivity and longevity (C), yet moderately 
attenuates behavior (D,E) and longevity (F) defects of TPI
G75E
.  It should be noted that mean thermal stress 
paralysis times near 360sec represent near-wild type behavior.  n≥30 for behavior, and n≥90 for lifespans.  ns 
indicates no significant, and *** p<0.001.  # indicates the animals did not paralyze (a score of 360 sec.). 
 
The incomplete complementation of TPI
G75E
 was unexpected; our previous experiments 
suggested that TPI
Δcat
 was sufficient to support normal behavior and longevity.  This observation 
alluded that TPI
Δcat 
alone was not sufficient for normal behavior and longevity, and could depend 
on productive interactions with the active isoform.  To examine this possibility, we measured the 
capacity of these TPI isoforms to co-precipitate using a cyan fluorescent protein (CFP) tagged 
variant of TPI
Δcat-CFP
.  The CFP tag was immunoprecipitated in TPI
+
/TPI
Δcat-CFP
, TPI
M80T
/TPI
Δcat-
CFP
, TPI
T74R
/TPI
Δcat-CFP
, and TPI
G75E
/TPI
Δcat-CFP
 animal lysates and probed.  Protein size was used 
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to discriminate between the two isoforms, as the CFP tag roughly doubled the weight of TPI.  
Robust levels of TPI
+
 precipitated with TPI
Δcat-CFP
, establishing substantial heterodimerization 
between the two species [Figure 18A,B].  Conversely, TPI
M80T
 and TPI
T74R
 displayed markedly 
reduced associations with TPI
Δcat-CFP
, reflecting their overall prevalence in the lysate [Figure 
18A] and corroborating their previously established dimerization deficiencies.  Finally, it was 
surprising to see that TPI
G75E
 produced heterodimerization similar to that seen in TPI
+
; it was 
predicted that the rotational flexibility of G75 was necessary for the appropriate positioning of 
loop 3 and establishment/rigidification of the dimer interface.  Further, our genetic data 
suggested that complementation required a productive interaction between TPI
∆cat
 and its partner, 
and based on these observations we predicted that TPI
G75E
 would lack such interactions, not 
maintain them.  This observation led us to generate a double mutant which contained both T74R 
and G75E, predicting that the T74R mutation would reduce enzyme heterodimerization as 
previously published (19).  
 
 
Figure 17.  Lysate isomerase activity does not predict disease presence of severity.  Lysate activity is 
indicated (A) and expanded (B) as per the dashed box.  ns indicates no significant differences and *** 
p<0.001.  Biological replicates are indicated. 
 
We generated a double mutant, TPI
T74R,G75E
 , and discovered that combining the two 
mutations resulted in an allele that closely resembled TPI
T74R
 with respect to animal toxicity, 
behavior, protein levels, and isomerase activity [Figure 19A,B,C].  Additionally, precipitation 
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experiments confirmed the addition of the T74R mutation to TPI
G75E
 also reduced its capacity to 
interact with TPI
Δcat-CFP 
[Figure 18A,B].  We repeated our complementation studies, generating 
TPI
+
/TPI
+
, TPI
+
/TPI
T74R,G75E
, TPI
T74R,G75E
/TPI
T74R,G75E 
and TPI
T74R,G75E
/TPI
Δcat
 animals.  
Characterization of these animals revealed the addition of the T74R point mutation to TPI
G75E
 
enhanced the behavioral attenuation of this dimer interface mutant by TPI
Δcat
; the mean time to 
recovery after mechanical stress was reduced from 204 sec. to 50 sec., with approximately 60% 
of the animals no longer responding to the stressor (defined as a recovery time ≤ 5 sec.).  This 
stood in contrast to TPI
G75E
, whose time to recovery after mechanical stress changed from 69 sec. 
to 82 sec. with approximately 30% of the animals no longer stress sensitive upon TPI
Δcat
 
complementation; thermal stress-sensitive phenotypes exhibited a similar trend.  Observing 
TPI
T74R,G75E
 lysate isomerase activity did not suggest a role for gross catalysis: TPI
Δcat
 
complementation resulted in a marked reduction in activity [Figure 19C] with positive behavioral 
affects.  Measuring animal longevity however yielded disparate results, as both TPI
T74R,G75E
 
homozygotes and TPI
T74R,G75E
/TPI
Δcat
 survived a median of 2 days.  It is important to note that 
this is the first example in which TPI deficiency behavior and longevity phenotypes have not 
been in congruence, and suggests the possibility that these effects are derived from different 
pathogenic sources.  We conclude that the allelic context-dependence of TPI
∆cat
 
complementation suggests a requirement for intermolecular interactions.  Further, it is clear that 
these interaction requirements differ for the purposes of longevity and behavior. 
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Figure 18.  Heterodimerization of inactive TPI and dimer interface mutations.  TPI
∆cat-CFP
 interacts 
modestly with TPI
M80T
, TPI
T74R
, and TPI
T74R,G75E
, yet robustly with TPI
G75E
.  Representative 
immunoprecipitation and input blots are shown (A) with IP: anti-GFP quantification (B) n=3.  ns indicates no 
significance, ** p<0.01, and *** p<0.001. 
3.3.5 Vesicle recycling at the synapse 
Seeing no obvious mechanistic trend from our genetic or biochemistry experiments, we turned to 
the phenotype to direct our next experiments.  In this regard, the TPI
T74R
 temperature-dependent 
paralysis was particularly striking, with a mean time to paralysis of 27 sec.  Acute (<60 sec.) 
temperature-dependent phenotypes have only been identified in a handful of mutants in all of 
Drosophila biology and result from neural conductance or synaptic defects (72).   
To determine whether TPI was playing a role in neural transmission, we first examined 
vesicle recycling efficiency at the synapse using the lipophilic dye, FM1-43FX.  Measuring 
recycling in this context allowed us to assess two possibilities; i) a primary recycling defect, or 
ii) a secondary recycling defect due to aberrant excitation or fusion.  We dissected larvae 
homozygous for TPI
+
, TPI
T74R
, and Shi
ts1
 as previously detailed (140).  The neuromuscular 
junction (NMJ) preparations were heated to 38°C over 3 min. and a loading curve was generated 
from a series of three different high [K
+
] loading times – 15 sec., 30 sec., and 60 sec. as 
previously detailed (141).  TPI
+
 displays a progressive increase in dye loading from 15 sec. to 60 
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sec. [Figure 20A], while the temperature sensitive dynamin mutant control Shi
ts1
 showed no 
signs of vesicle recycling at any heated time points [Figure 20D, data not shown].  Conversely, 
although TPI
T74R
 displayed similar loading to TPI
+
 at 15 and 30 sec., TPI
T74R 
exhibited a striking 
50% decrease in loading at 60sec. [Figure 20A,B,D].  This precipitous decrease in loading is 
temperature dependent [Figure 20C] and corroborated roughly with the mean time to paralysis in 
these animals (27sec).  To examine the relationship between vesicle recycling and animal 
behavior, TPI
T74R/∆cat
 larvae were assessed, and loading experiments demonstrated a significant 
increase in vesicle recycling [Figure 20B,D] corroborating the behavioral complementation 
[Figure 16B].  The utilization of chemical stimulation in these preparations demonstrates a 
synaptic defect arising from the severe TPI
T74R
 dimer mutation, as this methodology bypasses 
conductance requirements.  Further, these mutations were revealed to have a purely functional 
impact on the synapse, as morphological characterizations of bouton number and branches 
revealed no significant differences relative to TPI
+
 [Figure 21].  Collectively, these data 
demonstrate that TPI Deficiency thermal-stress sensitivity is elicited through inhibition of 
synaptic vesicle recycling. 
The identification of a synaptic phenotype generated increasing interest in the possibility 
that these dimer interface mutations may be altering the stability of the enzymes, thereby 
inhibiting transport and maintenance at distal sites.  To independently assess this possibility, we 
engineered a series of permutations of the R188 residue.  This R188 residue forms a well-
described and entirely conserved salt bridge with D224, helping to stabilize the overall TIM 
barrel structure (142).  We predicted that if stability and putative localization of activity were the 
key elements to pathogenesis, with dimerization being a contributing determinant, we should be 
able to observe phenotypes in these animals as well.  We engineered TPI
R188A
, TPI
R188L
, and 
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TPI
R188S
 mutants to examine different biochemical exploitations of this salt bridge, as previously 
assessed (142).  Additionally, we included a TPI
R188K
 control to maintain the charged interactions 
in this region, again as previously established (142).  Upon generating these animals, it was 
noted that TPI
R188A
, TPI
R188L
, and TPI
R188S
 proved homozygous lethal.  Conversely, TPI
R188K
 was 
homozygous viable, easily maintained as a homozygous stock, and exhibited no mechanical or 
thermal stress sensitivities as a homozygote or trans-heterozygote over TPI
null
 [data not shown]. 
Establishing these initial viability phenotypes, we sought to confirm their levels in vivo, 
and to do so required mating these alleles with those encoding CFP-tagged TPI
+
 for animal 
viability and to discriminate between species (TPI
WT-CFP
) (1).  Immunoblot results corroborated 
our viability data, with all the lethal TPI
R188
 alleles exhibiting dramatic reductions in protein 
levels [Figure 22B,D].  The low levels of these proteins necessitated an overexposure of the blot 
to even see evidence of these species [Figure 22D].  Next, we sought to examine the ability of 
TPI
∆cat
 to complement these stability mutants.  We found that the inactive allele restored viability 
in TPI
R188A
/TPI
∆cat
, and TPI
R188S
/TPI
∆cat
, but oddly not TPI
R188L
/TPI
∆cat
.  Observing the tagged 
protein levels of TPI
WT-CFP
, however, suggested that TPI
R188L
 may have a dominant capacity to 
induce degradation of its partner [Figure 22C,D].   
To examine behavior, we aged the animals at 25°C and tested them on day 3, as this has 
been shown to be an optimal time to discriminate behavioral effect in Drosophila TPI deficiency 
(1).  Importantly, even though TPI
∆cat
 was capable of complementing the lethality in these 
animals, they still displayed signs of behavioral dysfunction [Figure 22A]; and although no 
formal longevity assays were performed, we noted reduced longevity.  These data suggest that 
even with the addition of a stable, inactive isoform of TPI, these animals likely experienced a 
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similar deprivation of TPI at critical locales much like the trans-heterozygote TPI
M80T
/TPI
null
.  
These data support a role for TPI stability in the pathogenesis of TPI deficiency. 
 
 
Figure 19.  TPIT74R,G75E behavioral dysfunction and longevity.  TPI
T74R,G75E
 is characterized by 
sever mechanical (A) and thermal (B) stress sensitivity, which responds positively to complementation by 
TPI
∆cat
.  TPI
T74R,G75E
 exhibits reduced lysate catalytic activity compared to WT (C).  TPI
∆cat
 fails to 
complement TPI
T74R,G75E
 longevity (D).  n≥30 for all behavior, n≥80 for all lifespans.  ns indicates no 
significance, ** p<0.01, *** p<0.001.  # indicates animals did not paralyze within 360sec. 
3.4 DISCUSSION 
TPI deficiency is a disease caused by insufficiencies  in subcellular catalytic activity.  This 
disruption of localized activity can be achieved through mutations that directly affect enzyme 
catalysis, transport, or stability.  Previous studies of TPI Deficiency have focused largely on 
molecular and cellular analyses of the disease-associated substitutions.  These structural studies 
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have revealed the importance of the dimer interface for maintaining protein stability.  
Conversely, cellular studies in yeast have revealed complex redox changes which occur as a 
function of inhibiting glycolytic flux.  This study builds upon previous structural work, but 
examines TPI Deficiency neuropathogenesis.  Using a Drosophila GE strategy, we have 
conclusively shown that neurological phenotypes seen in TPI Deficiency are attributable to 
impaired vesicle recycling at the synapse.   
3.4.1 Triosephosphate isomerase dimerization 
In this report we describe the M80T substitution as impairing TPI dimerization.  These results 
were obtained from purified proteins and do not corroborate those from non-denaturing gel 
filtration experiments from animal lysates.  However, several in vitro studies have found that 
mutations which render TPI a monomer severely destabilize the protein (17,19,143-145).  In 
vivo, unstable proteins are bound by chaperones and either refolded, targeted to the proteasome, 
or aggregate (146).  The results presented here suggest that M80T does not cause TPI to 
aggregate [Figure 15], while previous work (86) extensively details the recruitment of Hsp70 and 
Hsp90 to TPI
M80T
 and its degradation through the proteasome.  Therefore, we hypothesize that 
TPI monomer was not previously detected in animal lysates due to its rapid sequestration and 
degradation.  Further, the TPI levels from each mutant closely correlate with their propensity to 
coprecipitate with TPI
∆cat-CFP
 [Figure 18A].  We believe these data, along with the previous 
inability to identify monomer in vivo, collectively suggest that TPI does not stably exist in vivo 
as a soluble monomer.   
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Figure 20.  TPI
T74R
 inhibits vesicle recycling at 38°C.  An FM1-43 timecourse at the NMJ with 
loading times of 15, 30, and 60sec (A), with quantification of 60sec at 38C (B) and 60sec at room temperature 
(RT) (C).  Representative images of TPI
+
, TPI
T74R
, TPI
T74R/∆cat
 and Shi
ts1
 (D).  n=6,  ***p<0.001. 
 
Once M80T was identified as having elicited a dimer defect, we used our GE system to 
generate two TPI alleles with point mutations at the dimer interface which had previously been 
described to impair homodimerization.  These mutations were located at the tip of the 3
rd
 loop of 
TPI which extends into its dimer partner and stabilizes/rigidifies a network of hydrophobic 
interactions and hydrogen bonds which form the dimer interface (18,19,147).  The substitution of 
these dimer interface residues resulted in extremely toxic TPI alleles, eliciting greater behavioral 
dysfunction and shorter lifespans than M80T [Figure 14].  The new mutant animal phenotypes 
were in contrast to our measurements of enzyme activity, which revealed that the dimer interface 
mutants exhibited reduced, yet substantial isomerase activity.  These data firmly establish a 
disjunction between toxicity/neurological dysfunction and gross isomerase activity.  However, 
the allelic differences in TPI
∆cat
 complementation suggested a role for the still-catalytically active 
mutant alleles as a determinant of animal survival and behavior [Figure 16]. 
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Figure 21.  TPI dimer interface substitutions do not alter NMJ development and morphology.  NMJ 
morphology of segment A2 muscle 6/7 was characterized for bouton number (B) and branching (C).  Neither 
parameter showed significant differences elicited by the mutations, relative to either TPI
WT
 or TPI
WT-
CFP
/TPI
WT
.  Representative images shown in (A).  n=10.  Scale bar = 10µm. 
Our previous work indicated that a properly folded, stable, inactive isoform of TPI fully 
complemented the loss-of-function dimer mutant, TPI
M80T
.  We sought to confirm this result by 
crossing that same catalytically inactive TPI allele with our new, more toxic dimer interface 
mutants.  We hypothesized that the inactive enzyme would be able to complement the TPI
T74R
 
and TPI
G75E
 alleles as it did TPI
M80T
.  We found that although TPI
Δcat
 complemented TPI
T74R
, it 
only moderately attenuated the behavioral dysfunction and longevity defects of TPI
G75E
 [Figure 
16].  From these data we concluded that TPI
Δcat
 was not sufficient to maintain normal animal 
health and behavior and may require productive intermolecular interactions.  It was curious that 
measurements of heterodimerization demonstrated that the extremely toxic and complemented 
TPI
T74R
 interacted very poorly with TPI
Δcat-CFP
, while the incompletely complemented TPI
G75E
 
maintained a robust capacity to bind TPI
Δcat-CFP
, similar to that of TPI
+
 [Figure 18].  Though 
these results reflected the proteins’ overall presence in the lysate, these observations were 
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unexpected; based on the genetic data we had predicted that TPI
T74R
 and TPI
M80T
 would have 
interacted more amiably while TPI
G75E
 less so.   
 
 
Figure 21.  TPI
∆cat
 rescues viability in strong TPI stability mutants, though not behavior.  TPI salt 
bridge mutants were crossed to TPI
∆cat
 and assessed for complementation.  Complementation with the 
inactive enzyme restores viability in two of three salt bridge mutants, yet all exhibit similar mechanical stress 
sensitivity as TPI
M80T
/TPI
null
 (A), n≥18.  Salt bridge mutants were complemented with TPIWT-CFP and exhibit 
dramatic reductions in lysate protein levels (D) with quantification (B).  No significant differences were noted 
in TPI
WT-CFP
 levels (D), quantified in (C), though blots of TPI
WT-CFP
/TPI
R188L
 exhibited a trend toward a 
reduction in the tagged protein, n=3.  *** indicates p<0.001. 
 
To explore the role of heterodimerization on TPI deficiency complementation we 
generated a double mutant allele bearing both T74R and G75E mutations.  The addition of T74R 
to the TPI
G75E
 allele indeed reduced its ability to physically interact with TPI
Δcat-CFP
 [Figure 18].  
Further, this lack of heterodimerization improved the efficacy of behavioral complementation via 
TPI
Δcat 
yet failed to alter toxicity [Figure 19].  It is currently unclear precisely why the 
TPI
T74R,G75E
 allele exhibits greater behavioral complementation compared to TPI
G75E
.  The results 
of these experiments suggest that either TPI
G75E
 is capable of interfering with the behavior-
relevant functions of TPI
∆cat
, or that T74R facilitates these interactions.  Yet the dominant 
negative hypothesis is contradicted by TPI
G75E’s inability to negatively modulate behavior or 
longevity when paired with a wild type allele.  This leaves us to hypothesize that T74R facilitates 
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a productive effect when paired with TPI
∆cat
, even though their heterodimerization is extremely 
limited. 
3.4.2 TPI mutations reduce vesicle recycling at the synapse 
The severity of the newly generated TPI dimer interface mutants provided insight regarding the 
anatomical source of pathology.  It was intriguing that the TPI
T74R
 allele exhibited temperature-
dependant paralysis at a mean time of approximately 27 sec.  As mentioned previously, this type 
of behavior is rare and highly enriched for synaptic or conductance defects.  Only a handful of 
mutant alleles have been identified with this type of behavior, including voltage-gated Na
+
, K
+
, 
and Ca
2+
 channels (para, sei, cac) (70,148,149), the sodium-potassium exchanging ATPase 
(ATPα) (109), and components of vesicle fusion and recycling (N-ethylmaliemide sensitive 
fusion protein – dNSF1, dynamin – Shi) (71,150).  Noting these phenotypic similarities we 
broadly examined synaptic function.  We found that the TPI
T74R
 mutant inhibited FM1-43 
loading at the synapse in a temperature dependant manner [Figure 20].  The TPI
T74R
 mutants 
were characterized by normal loading during acute exposures (15 and 30 sec.) but exhibited a 
dramatic reduction at 60sec. [Figure 20A], suggesting a time/excitation dependant phenotype.  
Further, complementation with the TPI
∆cat
 allele significantly increased the temperature-
dependent FM1-43 loading at these terminals, much like the allele complements the adult 
thermal stress behavioral phenotype.  Collectively, these data establish that impaired vesicle 
recycling is the pathophysiologic mechanism underlying the thermal stress dependent paralysis. 
It has previously been demonstrated that functional as well as developmental changes at 
the synapse can influence vesicle recycling.  Of note, trans-synaptic signaling components of the 
Glass bottom boat (Gbb – a bone morphogenic protein)/Wingless (Wnt)/Transforming growth 
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factor beta (TGF-β) pathways have been shown to modulate synaptic growth and activity (151-
155).  Given the reduced developmental viability of the TPI
T74R
 and TPI
G75E
 alleles, we examined 
whether these substitutions may be altering functional properties of the synapse through a 
primary change in development.  To assess development, we quantified neuromuscular junction 
(NMJ) 6/7 morphology at segment A2 [Figure 21], the same NMJs used for the functional FM1-
43 dye uptake assays.  Our analyses revealed no morphological changes in this NMJ as a 
function of our dimer mutations, supporting a primary functional defect of TPI Deficiency on 
vesicle recycling at the synapse [Figure 21].   
The observed synaptic defect also provided insight into to why the majority of human 
disease-associated TPI mutations occur at the dimer interface.  First, all substitutions which 
disrupt the dimer interface have been shown to destabilize the enzyme in vitro (18,19,147).  This 
destabilization is likely responsible for the reduced cellular TPI found in patient samples, and our 
work with the TPI
M80T
, TPI
T74R
, and TPI
G75E
 mutants support a reduction in TPI levels in vivo as 
a function of dimer interface substitutions [Figure 14D,E].  Secondly, the cellular depletion of 
TPI
M80T
 has been shown to be mediated by heat shock protein sequestration and proteasomal 
degradation (86).  If chaperones sequestered and degraded these misfolded or unstable proteins, 
this would likely prevent the distribution and maintenance of TPI activity at specific subcellular 
locales.  Finally, recent work has shown that the anterograde transport of globular/soluble 
proteins to the terminals is a slow process, moving at a rate of approximately 0.008-0.01µm/sec 
(156).  To put this in the context of the Drosophila nervous system, the length of the relatively 
short larval motor axon innervating muscle 4 of segment A3 has been measured to be ~220µm 
(157).  Based on these approximations, one could estimate that it would take ~6hrs for TPI 
translated in the soma to be transported to the terminal.  In this way, substitutions which affect 
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protein stability likely result in improper localization or sequestration of TPI during distal 
transport.   
To examine the potential for stability mutations independent of the dimer interface to 
elicit pathology, we generated mutants of the entirely conserved R188-D224 salt bridge, 
previously shown to be critical to enzyme stability (142).  The TPI
R188A
,
 
TPI
R188L
,
 
and TPI
R188L
 
substitutions proved lethal, while the conservative TPI
R188K
 substitution behaved like wild type.  
Previous data establishing changes in stability, and our lethality observations, corroborated the 
dramatic reductions of these proteins in animal lysates [Figure 21B,D].  It was intriguing that the 
TPI
∆cat
 allele was capable of complementing two of the three lethal alleles to viability, yet these 
trans-heterozygotes (TPI
R188A
/TPI
∆cat
 and TPI
R188S
/TPI
∆cat
) exhibited behavioral dysfunction, 
much like the partially complemented TPI
G75E
 and TPI
T74R,G75E
.  These data support the 
hypothesis that dimer mutations elicit pathology by changing the stability of TPI. 
The biochemical mechanism through which TPI regulates synaptic function is not yet 
known, but our work and that of others strongly suggests the importance of catalytic 
microdomains at the synapse.  These conclusions are based on the genetic indications of allelic 
interdependence for complementation, TPI Deficiency impaired vesicle recycling, and work by 
others detailing the importance of glycolysis-derived ATP for synaptic vesicular endocytosis 
(135,158).  Indeed, recent work quantifying the ATP consumption in the synapse demonstrated 
that the vesicle cycle represents the greatest ATP burden at the terminals, and this was further 
supported by the cessation in vesicle endocytosis during the inhibition of glycolysis and 
oxidative phosphorylation (OXPHOS) (135).  Of particular note was that inhibition of glycolysis 
had a more dramatic effect on the vesicle cycle compared to that of OXPHOS.  Inhibition of 
glycolysis was also noted to have a more dramatic effect on overall ATP production in the 
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terminal relative to OXPHOS.  These observations suggested that glycolysis, rather than 
OXPHOS, is the primary means through which neural activity drives ATP production.  Further, 
mutations in Drosophila phosphoglycerate kinase, an ATP-producing step of glycolysis, have 
previously been demonstrated to reduce vesicle recycling (158).  Our data and the work of others 
strongly suggests that TPI facilitates the local production of glycolytic ATP, and the subcellular 
localization of this deficiency is the ultimate determinant of neurological dysfunction.  
3.5 MATERIALS AND METHODS 
3.5.1 Animal Strains 
The Vienna Drosophila RNAi Center (VDRC) line used for knockdown experiments was stock 
#25644 (136).  The w;actin-GAL4,UAS-GAL4; animals were generated by recombining the 
second chromosomes of the Drosophila Genetic Resource Center (DGRC) stock #108492 and 
Bloomington Stock Center stock #4414; recombinants were screened molecularly and balanced.  
All TPI alleles used in this study were generated using the GE system: TPI
+
, TPI
M80T
, TPI
T74R
, 
TPI
G75E
, TPI
T74R,G75E
, TPI
Δcat
, TPI
R188A
, TPI
R188K
, TPI
R188L
, TPI
R188S
, and TPI
Δcat-CFP
.  The 
development of the GE system and the production of the TPI
+
, TPI
M80T
, TPI
Δcat
, and TPI
Δcat-CFP
 
alleles were initially described elsewhere (1).  It is important to note that the numbering used in 
this study utilizes the established nomenclature for TPI mutations, assuming the start methionine 
is removed following translation (45); and for consistency all residue numbering in this study 
uses the same convention.  Care was taken to ensure all animal populations assessed were 
approximately equivalent mixtures of males and females. 
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3.5.2 Mutagenesis and Genomic Engineering 
Site directed mutagenesis was performed using the QuikChange Lightening Site-Directed 
Mutagenesis Kit (Agilent Technologies).  Mutagenesis primers were generated (Integrated DNA 
Technologies) to introduce a Thr-to-Arg codon change at position 74, and a Gly-to-Glu change 
at position 75 – both separately and together for the purpose of creating the double-mutant.  
Additionally, primers were generated to create Arg-to-Ala, Arg-to-Lys, Arg-to-Leu, and Arg-to-
Ser mutations at position 188.  Mutagenesis was performed on the previously published pGE-
attBTPI
+
 plasmid and confirmed by sequencing.  Once the constructs were generated, TPI GE 
was performed using previously published methods (1,99,100).  Briefly, the PGX-TPI founder 
animals were mated to vasa-phiC31
ZH-2A
 animals expressing the integrase on the X chromosome 
and their progeny injected with pGE-attBTPI constructs.  Integration events were identified via 
the w
+
 phenotype and verified molecularly.  
3.5.3 Human TPI enzyme purification 
Human TPI enzyme was purified as outlined previously (1).  Briefly, the coding sequence for 
H.sapien TPI was cloned into the bacterial expression vector pLC3 using standard techniques.  
The resulting plasmid directs expression of TPI containing N-terminal His6- and MBP tags, both 
of which can be removed with TEV protease. TPI protein was expressed in BL21(DE3) Codon-
Plus (RILP) E. coli (Agilent Technologies) grown in ZY auto-induction media (131) at room 
temperature for 24–30 hours. Cells were harvested by centrifugation, lysed via homogenization 
in 25 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 5 mM imidazole, 1 mM β-mercaptoethanol 
and cleared by centrifugation at 30,000 g. TPI was purified by nickel affinity chromatography 
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followed by overnight TEV protease treatment to cleave the His6-MBP tag from TPI. A second 
round of nickel affinity purification was performed to separate the His6-MBP and TEV protease. 
TPI protein was further purified using cation-exchange chromatography (HiTrap-QP) followed 
by gel filtration (Sephacryl S-200, GE Healthcare). Peak fractions were concentrated to 4–8 
mg/ml in 20 mM Tris pH 8.8, 25 mM NaCl, 2.0% glycerol and 1 mM β-mercaptoethanol using a 
Vivaspin concentrator (GE Healthcare). The purity was >99% as verified by SDS-PAGE. 
3.5.4 Dynamic Light Scattering 
DLS measurements were taken using a DynaPro Plate reader (Wyatt Technology) equipped with 
a temperature control unit.  Purified BSA (Sigma Aldrich), hTPI
+
 and hTPI
M80T
 were diluted to 
concentrations of 5μM, 15μM and 30μM in 100mM triethanolamine (TEA); pH 7.6.  Aliquots of 
75μl were loaded in triplicate onto a 384-well microplate and read at 37°C.  Ten measurements 
were taken per sample and Dyanmics V6 software (Wyatt Technology) was used to process the 
scattering data, generating autocorrelation functions.  Autocorrelation functions were then 
analyzed to obtain the hydrodynamic radii.  Student’s T test was used to compare samples.  
3.5.5 Gel Filtration Chromatography 
Gel filtration was performed as outlined previously (85).  Briefly, separations were performed 
with a Shimadzu high performance liquid chromatography (HPLC) system using a Superdex 
75/300 GL column (Amersham Biosciences) set to a flow rate of 0.4 ml/min at room 
temperature.  A non-denaturing mobile phase was selected consisting of 25mM NaH2PO4, 25mM 
Na2HPO4, 150mM NaCl; pH 7.0.  The column was calibrated with a Low Molecular Weight Gel 
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Filtration Calibration Kit (GE Healthcare Life Sciences) according to the manufacturer’s 
instructions.  Calibration standards included Aprotinin (6.5kDa), RNAase A (13.7kDa), Carbonic 
Anhydrase (29kDa), Ovalbumin (44kDa), and Conalbumin (75kDa).  Purified TPI samples were 
diluted to 15μM in mobile phase and 100μl were injected and measured in triplicate, and their 
elution monitored at 280nm.  Chromatography traces were collected and analyzed using EZStart 
7.3 (Shimadzu) to quantify the relative monomer and dimer populations.  Curve integration data 
were compared using Student’s T test. 
3.5.6 TPI Enzyme Assays 
Isomerase activity was determined using an NADH-linked assay as previously detailed (1,132).  
Briefly, animals aged 1-3 days were collected and frozen in liquid nitrogen.  Bodies lacking 
heads or appendages were isolated and homogenized in 100mM TEA pH 7.6 supplemented with 
cOmplete mini Protease Inhibitors (Roche Diagnostics).  The homogenates were sonicated in an 
ice bath for 10min and centrifuged twice at 4°C for 5min at 5,000g to remove exoskeletal debris.  
Lysates were diluted to 0.1μg/μl in 100mM TEA pH 7.6 + inhibitors and enzyme activity was 
assessed.  Reaction assays were performed using 80μl mixtures composed of 0.5mM NADH, 
0.752mM GAP, 1 unit glycerol-3-phosphate dehydrogenase and 1μg of lysate protein in 100mM 
TEA; pH 7.6.  Consumption of NADH was monitored at 340nm using a SpectraMax Plus 384 
microplate reader (Molecular Devices).  All reactions were performed in both experimental and 
biological triplicate.  Reaction components were purchased from Sigma-Aldrich.  Enzyme 
activity curves were normalized to reactions performed without GAP.  A one-way ANOVA was 
performed to assess variance and data sets were compared using Tukey’s post-hoc analysis.  
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3.5.7 Behavioral testing and lifespan analysis 
Mechanical stress sensitivity was examined by vortexing the animals in a standard media vial for 
20 seconds and measuring time to recovery, similar to (133). Thermal stress sensitivity was 
assessed by acutely shifting animals to 38°C and measuring time to paralysis, as previously 
described (65,109). Behavioral responses were capped at 360 and 600 seconds where indicated.  
Animal lifespans were performed at 25°C as previously described (109). One-way ANOVAs 
were performed with Tukey's post test to compare behavior, and lifespans were assessed with 
Log-rank (Mantel–Cox) survival tests. 
3.5.8 Immunoblots 
Animals were collected aged 1-2 days at room temperature. Ten fly heads were obtained in 
triplicate from each genotype and processed as outlined previously (86). Briefly, the fly heads 
were ground by pestle in 80 µl 2× SDS–PAGE sample buffer (4% SDS, 4% β-mercaptoethanol, 
130 mM Tris–HCl pH 6.8, 20% glycerol) and centrifuged for 5 minutes at 5000 g to pellet the 
exoskeleton.  Proteins were resolved by SDS–PAGE and transferred onto 0.45μm PVDF 
membrane. Following treatment in 1% milk PBST, the blots were incubated with anti-TPI 
(1∶5000; rabbit polyclonal FL-249; Santa Cruz Biotechnology) or anti-ATPalpha (1∶10,000; 
mouse monoclonal alpha5; Developmental Studies Hybridoma Bank).  The blots were washed in 
PBST, incubated in the appropriate HRP-conjugated secondary antibody, and developed using 
ECL (Pierce).  Densitometric analyses of the scanned films were performed digitally using 
ImageJ software available from the National Institutes of Health.  A one-way ANOVA was 
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performed to assess variance of TPI levels and data sets were compared using Tukey's post-hoc 
analysis. 
3.5.9 Filter-trap Dot Blot 
The filter-trap dot blot was modified from methods published previously (139).  Animals were 
aged 1-2 days, collected and homogenized in 1X PBS (2.7mM KCl, 137mM NaCl, 2mM 
NaH2PO4, 10mM Na2HPO4; pH 7.4) supplemented with cOmplete mini Protease Inhibitors, and 
diluted to 1μg/μl.  Samples were diluted 1:2 in 1% SDS, 1X PBS, boiled for 5min, and filtered 
through a cellulose acetate membrane (Whatman, 0.2μm pore) using a 96-well vacuum dot blot 
apparatus.  Positive controls were collected from PC12 cells stably expressing huntingtin exon1 
with a stretch of 97 glutamines and C-terminally tagged with GFP.  The membrane was washed 
four times with the 1% SDS-PBS and blocked with Odyssey Blocking Buffer (LiCor), and 
primary antibodies applied in Odyssey Blocking Buffer.  Blots were incubated with anti-TPI 
(1:5000) and anti-GFP (1:5000) (Santa Cruz Biotechnology).  The membranes were then washed 
and incubated with the secondary antibody IRDye 800-conjugated goat anti-rabbit (LiCor) at 
1:20,000 in the same buffer used for the primary antibodies. Direct-to-scanner detection and 
band visualization were performed using a LiCor Odyssey scanner. 
3.5.10 Coimmunoprecipitations 
Coimmunoprecipitations were performed using the Pierce® Co-Immunoprecipitation Kit 
(Thermo Scientific) as per manufacturer’s instructions.  Lysates were generated by mechanically 
homogenizing 50 animals in 0.5ml of IP Lysis buffer (25mM Tris, 150mM NaCl, 1mM EDTA, 
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1% NP-40, 5% glycerol; pH 7.4) supplemented with cOmplete mini Protease Inhibitors.  After 
homogenization, lysates were frozen and thawed in liquid nitrogen, then centrifuged twice at 
5,000g to pellet exoskeletal debris.  Supernatants were collected and diluted to 1μg/μl and 400μg 
were loaded onto 25μl of gel pre-coupled with 10μg of anti-GFP (Santa Cruz).  A negative 
control was performed using uncoupled gel and TPI
+
/TPI
Δcat
 lysate.  Samples were incubated 
overnight at 4°C and washed ten times with IP Lysis buffer at 4°C.  Beads were eluted with 70μl 
of 2X SDS–PAGE sample buffer, separated via SDS-PAGE, immunoblotted, and analyzed as 
outlined above.  Coimmunoprecipitations were performed in biological triplicate. 
3.5.11 FM1-43 Imaging Experiments 
Images were taken with an Olympus BX51WI fluorescence microscope with Till Photonics 
Polychrome V monochromater excitation, and Hamamatsu C4742-95 digital camera.  
Heterozygous TPI
T74R
 larvae were maintained over TM6B and Tb
+
 3
rd
-instar larvae selected for 
analysis.  Dissection and preparation of larval NMJs were performed as outlined previously 
(140).  FM1-43FX dye [Molecular Probes, Invitrogen] loading was performed as previously 
detailed (141).  Briefly, animals were dissected in ice cold 0mM Ca
2+
 HL-3 with 0.5mM EGTA, 
then heated to room temperature or 38°C over the course of 3 min.  Bath temperature was 
monitored throughout the experiments with a microthermal probe to ensure consistency [Fisher 
Scientific].  Loading experiments were performed with room temperature or 38°C preheated 
90mM KCl 1.5mM CaCl2 Hl-3 supplemented with 4µM FM1-43FX, and preparations were 
washed quickly and thoroughly during the experiments to avoid Ca
2+
 chelation.  After loading, 
preparations were washed with 15ml of 0mM Ca
2+
 HL-3 with 0.5mM EGTA at room 
temperature for 10 min.  Preparations were immediately imaged with a water immersion 60X 
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objective, using 450nm excitation and a 500 nm longpass filter [Chroma Technology].  Simple 
PCI imaging software was used for acquisition and ImageJ for analysis.  Two NMJs from 
muscles 6/7 were assessed per animal, one from segment A2 and A3.  Six biological replicates 
were assessed per genotype per time point for a total of 12 NMJs per experimental condition.  
Boutons were defined as being greater than or equal to 2µm in diameter, and background 
intensity was subtracted from adjacent tissue.  Image analysis was performed blinded, with all 
file names relabeled by an independent researcher.  Pair-wise analyses were performed using a 
two-tailed Student’s t test, while comparisons among multiple experimental conditions was 
performed using a one-way Analysis of Variance (ANOVA) with Tukey’s post-hoc analysis. 
3.5.12 NMJ morphological analyses 
For NMJ morphological analyses, 3
rd
-instar larvae were collected and dissected as 
detailed above, without transection of the descending motor neurons.  Preparations were fixed in 
3.5% paraformaldehyde HL-3, permeabilized with 0.1% Triton X-100 in 1X PBS (PBST), and 
blocked with 0.2% BSA in PBST (PBSTB) for 2hrs.  Preps were washed and incubated with goat 
anti-HRP [Jackson Laboratories] at 1:200 in PBSTB for 2hrs.  Primary antibodies were removed, 
washed in PBSTB, and incubated with Cy3-labeled donkey anti-goat in PBSTB at 1:400 for 
1.5hrs.  Preps were washed, mounted in VectaShield [Vector Laboratories], and imaged within 
three days.  Images were acquired with an Olympus confocal FV1000 microscope, using a 
559nm excitation laser.  Z stacks of segment A2 of muscle 6/7 were taken using 1µm steps, and 
the start and end of the stacks were set just outside the range of the NMJ.  The Z stacks were 
merged using Olympus FV1000 Fluoview Viewer, and morphology determined.  Ten biological 
replicates were assessed per genotype, one NMJ per animal, for a total of ten NMJs per 
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experimental condition.  Boutons were defined as varicosities at least 2µm in diameter, and 
branches defined as extensions containing at least 2 boutons.  Images were relabeled by an 
independent researcher for blinded analysis.  Variance within the data set was examined using a 
one-way ANOVA, with comparisons made using Tukey’s post hoc test. 
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4.0  HUMAN TRIOSEPHOSPHATE ISOMERASE I170V ALTERS CATALYTIC 
SITE, ENHANCES DIMERIZATION AND INDUCES PATHOLOGY IN A 
DROSOPHILA MODEL OF TPI DEFICIENCY 
4.1 ABSTRACT 
Oligomerization is often an important regulator of protein function.  The formation of an 
oligomer can be simple or complex, uniting two homologous subunits, or assembling multiunit 
heterocomplexes.  Modifying the way proteins associate can have tremendous pharmacologic 
and pathologic implications.  Triosephosphate isomerase (TPI) is a glycolytic enzyme which 
homodimerizes for full catalytic activity.  Mutations of the TPI gene elicit a disease known as 
TPI deficiency, a glycolytic enzymopathy noted for its unique severity of neurological 
symptoms.  Recently, a high-resolution structure of one disease-associated TPI mutation 
revealed an alteration of the homodimer interface resulting in a reduction in enzyme stability, 
and not catalytic activity.  This study suggested that TPI deficiency pathogenesis may be due to 
conformational changes of the protein, likely affecting dimerization and protein stability.  In the 
present report, we genetically and physically characterize a previously unstudied human disease-
associated TPI mutation, which confers an I170V substitution.  TPI
I170V
 elicits behavioral 
abnormalities in Drosophila, and purified protein reveals dramatic increases in substrate affinity, 
enhanced enzyme dimerization, and increased thermal stability.  A high-resolution crystal 
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structure of the homodimeric I170V mutant reveals changes in catalytic site morphology.  
Collectively these data reveal new insights into the structural determinants of TPI deficiency 
pathology, and suggest new means of disease pathogenesis. 
4.2 INTRODUCTION 
Protein oligomerization is a phenomenon seen in many facets of biology.  The ability to 
create and stabilize complex quaternary structures from simple subunits is seen in the generation 
of glycolytic enzymes (159-161), receptor tyrosine kinases (162,163), actin filaments (164), 
vesicle fusion proteins (165,166), and countless other examples.  One of the most commonly 
used protein structures in nature is the β/α TIM barrel.  The TIM barrel is the structural base of 
over one hundred different enzymes, but was first identified in triosephosphate isomerase (TPI).  
TPI uses the TIM barrel to form the tertiary structure of its monomers, and like many other TIM 
barrel proteins, only functions as an oligomer/dimer in vivo.  TPI monomers in vitro exhibit little 
catalytic activity (18,19), but attain diffusion-limited catalytic properties upon dimerization (20).  
Structural analyses of artificial monomeric TPI variants have revealed flexibility of normally 
rigid motifs in and around the catalytic pocket (18,19).  These studies concluded that 
dimerization facilitates the rigidification of the catalytic pocket through a variety of trans-
monomeric Van der Waals forces, hydrogen bonds, and salt bridges (107), but little work has 
been done to examine the role of the catalytic site on the formation or maintenance of the 
homodimer. 
Functionally, TPI is a glycolytic enzyme that isomerizes dihydroxyacetone phosphate 
into glyceraldehyde 3-phosphate.  This isomerization occurs at a non-linear step in the catabolic 
 84 
process, enhancing the efficiency of glycolysis, and is not required for the production of 
pyruvate.  Mutations within the TPI coding region lead to a recessive disease known as TPI 
Deficiency, which is characterized by hemolytic anemia, neurologic dysfunction and often early 
death (26).  TPI Deficiency is unique among all other glycolytic enzymopathies in the 
presentation of severe neurological deficits and the lack of ATP depletion (45).  It is not 
currently understood why mutations in a non-linear glycolytic enzyme elicit far greater 
pathology than other central glycolytic enzymes, though recent work has suggested that these 
neurological differentia are derived from a source other than general metabolic stress (1).  To 
date, only one disease-associated TPI mutation has been structurally characterized (63).  
Additional physical analyses of disease-associated substitutions are clearly needed to more fully 
understand the unique pathology associated with TPI Deficiency. 
In the present report, we have investigated a poorly studied human disease-associated 
mutation of TPI which occurs at the catalytic lid of the enzyme.  Previously, patients bearing the 
I170V substitution had only been identified in a trans-heterozygous state with the more common 
E104D missense mutation (102).  Due to the rarity of this particular point mutation, it was 
previously unclear whether I170V was viable as a homozygote, pathogenic, or simply lacked 
sufficient consanguinity for observation.  Our work has revealed that I170V is homozygous 
viable and elicits behavioral dysfunction in a Drosophila model of TPI deficiency.  Further, in 
vitro measurements of TPI
I170V
 dimerization indicated a more robust homodimer population than 
WT, an observation corroborated by increased thermal stability of the TPI
I170V
 enzyme.  A 
crystal structure of TPI
I170V
 revealed a predominantly closed lid conformation, changes in the 
positioning of S96, and a water network coordinating E165 and H95.  Our data establish that the 
disease-associated I170V substitution is sufficient to alter both catalytic and dimerization 
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properties.  These data support and contrast the findings of the only previous structural analysis 
of a disease-associated TPI substitution, reaffirming the importance of enzyme dimerization in 
TPI deficiency pathology, but demonstrating a unique pathogenic increase in dimerization and 
stability.  These findings are critical to the understanding of the unique pathology associated with 
TPI deficiency, and suggest either a physiologic role for TPI in catalytic microdomains, or the 
necessity of dynamic regulation of the TPI dimer. 
4.3 RESULTS 
4.3.1 I170V induces behavioral dysfunction in Drosophila 
We initiated this study seeking to examine the toxic potential of the TPI
I170V
 allele.  Using 
our Drosophila genomic engineering (GE) system (1), we generated novel alleles of human TPI 
with an I170V substitution (hTPI
WT
 and hTPI
I170V
).  A GE approach is optimal for examining this 
type of dose-dependant loss-of-function disease, as it seamlessly places the modified alleles 
directly into the Drosophila TPI gene locus ensuring endogenous expression at all developmental 
stages and in all tissues (99,101).  Due to the relative abundance of null TPI alleles, many TPI 
deficient patients are genetically identified as trans-heterozygotes with a point mutation over a 
null allele (26,45).  hTPI
I170V
 proved homozygous viable, and we generated trans-heterozygous 
populations and assessed two genotypes: hTPI
WT
/TPI
null
 and hTPI
I170V
/TPI
null
.  The TPI
null
 allele 
is a deletion of two of the three exons of the TPI gene (formerly called TPI
JS10
) (50) while 
hTPI
WT
 is the human WT enzyme.   
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FIGURE 23.  hTPI
I170V
 is characterized by behavioral dysfunction but not reduced longevity.  
hTPI
I170V
/TPI
null
 exhibits mechanical (A) and thermal (B) stress sensitivity relative to hTPI
WT
/TPI
null
, n>20.  
Conversely, hTPI
I170V
/TPI
null
 demonstrated similar lifespans (C) as hTPI
WT
/TPI
null, n≥120.  * indicates p<0.05, 
** p<0.01, and *** p<0.001. 
 
We collected animals, aged them at 25°C, and examined their mechanical- and thermal-
stress sensitivity and longevity, as these phenotypes have been shown to be hallmarks of 
Drosophila TPI Deficiency (1,50,64,85).  Mechanical- and thermal-stress sensitivity were 
detected in hTPI
I170V
/TPI
null
 animals at both early (day 3 and 4) and late (day 20 and 22) time 
points, indicating progressive behavioral dysfunction [Figure 23 A,B].  A slight change in 
thermal stress sensitivity was noted in the wild type populations, with a fraction of the population 
exhibiting abnormal thermal stress-dependent behavior.  These effects on WT are not observed 
in homozygote animals, and we believe that this modest effect is likely a reflection of the 
heterozygote state (hTPI
WT
/TPI
null
).  Interestingly, we did not detect a significant change in 
longevity when comparing hTPI
I170V
/TPI
null
 versus hTPI
WT
/TPI
null
 [Figure 23C].  These results 
suggest Drosophila TPI Deficiency behavioral dysfunction and longevity phenotypes may be 
derived from different pathogenic sources. 
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4.3.2 in vivo TPI protein levels and enzyme activity 
Having identified aberrant behavior in the hTPI
I170V
 mutants, we sought to assess lysate 
isomerase activity and protein levels in this mutant.  An analysis of wild type protein structure 
predicted that the I170V substitution would likely influence catalytic properties due to its 
positioning on the catalytic lid of the enzyme [Figure 28].  Previous studies using a transgenic 
expression system in yeast identified a reduction in isomerase activity due to I170V (62), and our 
experiments measuring hTPI
+
 and hTPI
I170V
 activity in animal lysates confirmed these 
observations in the native gene locus [Figure 24A].  Of note though, a previous study in 
Drosophila failed to find a link between animal metabolism and disease phenotypes (1).  This 
former study suggested that a conformational change or depletion of cellular TPI elicited 
Drosophila TPI deficiency (1).  To examine the possibility that I170V may reduce protein levels 
in our system, we examined TPI levels in our newly generated alleles.  Western blots indicated 
no changes in TPI protein levels due to the I170V substitution relative to TPI
WT
 [Figure 24B,C], 
concluding the I170V mutation does not elicit pathology through a depletion of cellular TPI.   
 
 
 
FIGURE 24.  hTPI
I170V
 exhibits reduced catalysis and normal cellular TPI levels.  Isomerase assays 
reveals hTPI
I170V
/TPI
null
 reduces lysate TPI activity relative to hTPI
WT
/TPI
null
 (A), n=3.  Independent samples 
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of human hTPI
WT
/TPI
null
 and hTPI
I170V
/TPI
null
 (#1,#2,#3) demonstrate similar levels of cellular TPI (C), with 
quantification (B), n=3.   ns indicates no significance. 
 
Table 3. hTPI
WT
 and hTPI
I170V
 kinetic parameters. 
 hTPI
WT
 hTPI
I170V
 
Km (GAP) (mM) 1.4 ± 0.1 0.049 ± 0.014 
kcat (GAP) (s
-1
) 1623 ± 181.1 75.8 ± 2.6 
kcat/Km (GAP ) (M
-1
 s
-1
) 1.2 x 10
6
 1.5 x 10
6
 
4.3.3 I170V enhances substrate affinity, stability, and dimerization in vitro 
The only study to structurally examine a TPI deficiency mutation found that the E104D 
substitution altered a trans-monomeric water network; this E104D substitution resulted in 
reduced enzyme dimerization and stability, but did not alter enzyme activity in vitro (63).  
Recombinant human hTPI
WT
 and hTPI
I170V
 was expressed and purified, and we examined their 
respective kinetic properties [Table 3].  It should be noted that both enzymes displayed typical 
Michaelis-Menten behavior [Figure 25].  hTPI
WT
 demonstrated properties similar to those 
previously published (145,167,168), while hTPI
I170V
 displayed a ~20 fold reduction in catalytic 
turnover [Table 3] and a ~30 fold increase in substrate affinity [Table 3].  The combined 
reduction in turnover and increased substrate affinity suggests the enzyme is preferentially in the 
occupied state.   
Since previous studies had indicated that dimerization was an important molecular 
contributor to TPI deficiency, we assessed TPI dimerization of hTPI
I170V
 using gel filtration 
[Figure 26].  Analyses of hTPI
WT
 at room temperature demonstrated a 80:20 equilibrium of 
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dimer-to-monomer, with two corresponding peaks eluting at 24 and 27 minutes [Figure 26A,B].  
Comparatively, the monomer peak was absent in all analyses of hTPI
I170V
 dimerization [Figure 
26A,B].  These results suggested the I170V substitution may somehow enhance TPI dimer 
stability.  Indeed, Ralser and colleagues (62) noted that while E104D impaired WT:mut 
heterodimer associations in a yeast two-hybrid (Y2H) system, the I170V mutation appeared to 
increase these interactions.  Our results suggest that their increase in Y2H signal was not likely 
due to aggregation or external factors, but that this TPI variant is intrinsically capable of eliciting 
an increase in these dimeric associations.   
 
Figure 25.  hTPI
WT
 and hTPI
I170V
 exhibit Michaelis-Menten behavior.   
 
Over the past two decades several groups have characterized the folding and unfolding 
kinetics of TPI from numerous species (19,147,169-174).  These studies have established that 
dimerization of TPI is a crucial determinant of protein stability, though several monomeric 
intermediates are also critical.  Far-UV circular dichroism (CD) spectra did not identify a gross 
change in protein folding at 20°C [Figure 27], but an assessment of thermal denaturing at 222 nm 
indicated a significant change in protein stability, with hTPI
WT
 and hTPI
I170V
 exhibiting 
monophasic denaturation with Tms of 46.5°C and 59.4°C respectively [Figure 26C].  Previous 
studies have shown that CD measurements of TPI thermal denaturing elicit monophasic 
transitions (167,175), lacking the capacity to resolve many of the still-folded monomeric 
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intermediates.  Importantly, these data indicate that hTPI
I170V
 increases its dimer population 
through an enhancement of enzyme stability.   
Occupancy of the catalytic site has been shown to stabilize the dimer (171,173).  Given 
the enhanced substrate affinity of hTPI
I170V
, we predicted that hTPI
I170V
 stability would be more 
responsive to substrate administration that hTPI
WT
.  Using DL-glycerol-3-phosphate (DL-GP), a 
GAP substrate analog (176-178), we measured the stability shift resulting from occupancy of the 
catalytic site.  The addition of DL-GP to hTPI
WT
 resulted in a 3.7°C increase in stability (Tm 
50.2°C), while DL-GP enhanced hTPI
I170V
 stability only 1.6°C (Tm 61.0°C).  Denaturation of 
hTPI
I170V
 and hTPI
WT
 were both observed to be irreversible, an observation similar to that of 
previous studies (63,179,180). 
 
 
 
FIGURE 26.  I170V increases TPI dimer stability relative to WT.  Gel filtration indicates a change in 
monomer:dimer ratios elicited by I170V relative to WT (A) with quantification (B).  CD thermal shift 
analyses demonstrate a stabilization of TPI due to the I170V substitution (C), and altered responsiveness to 
5mM DL-GP substrate analog.   * indicates p<0.05, ns indicates no significance. 
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4.3.4 The crystal structure of I170V supports a preferentially closed catalytic pocket 
TPI is a TIM barrel protein, using the β/α barrel as a base for the orientation of its accessory 
loops.  The I170 residue is located on the rigid tip of loop 6 [Figure 28A].  Loop 6 of TPI forms a 
“lid” over the catalytic pocket, and its closure over the substrate has been shown to prevent the 
dissociation of catalytic intermediates during substrate isomerization (13).  Previous studies have 
described loop 6 as dynamic in the unbound state, and indeed NMR studies have shown 
breathing motions in this loop (181).  The lid is composed of three main components – an N 
hinge, a rigid tip, and a C hinge (182).  The N hinge extends immediately from the catalytic 
E165 and contains a three residue sequence of P166-V167-W168 (180).  The P166 provides 
rigidity to the hinge mechanism while the bulky hydrophobic V167 is positioned to facilitate lid 
movement.  The N terminal hinge works in conjunction with a C terminal hinge, composed of 
K174-T175-A176 (179,183).  Changes in phi and psi angles of T175 are believed to promote 
changes in lid orientation (182). 
 
Figure 27.  Averaged far-UV CD spectra of hTPI
WT
 and hTPI
I170V
 acquired during thermal 
denaturation. 
To determine if we could visualize the molecular mechanism responsible for the altered 
hTPI
I170V
 catalytic properties, we purified, crystallized and analyzed the structure of hTPI
I170V
 at 
2.0Å resolution.  hTPI
I170V
 was crystallized in a buffer nearly identical to that of hTPI
WT
 (1.6Å), 
facilitating a near-atomic comparison.  The overall folding of the enzymes was similar, 
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corroborating our previous CD analyses [Figures 27-29].  In both structures, a bromide ion from 
the crystallization conditions was found in the active site, as was a phosphate ion which was not 
added intentionally, and which presumably co-purified with TPI.  The positioning of these ions 
directly overlap those of substrate molecules co-crystallized with other TPI structures, suggesting 
their inclusion helped stabilize the catalytic pocket during crystallization.  
The I170V structure revealed a change in the region surrounding the N hinge; specifically 
a ~90° rotation of S96, moving its terminal proton 2.7Å toward the catalytic site [Figure 28A].  
S96 is known to rotate in and out of the catalytic site with the movement of the lid.  In an open 
lid conformation, S96 rotates inward and hydrogen bonds with E165, stabilizing its localization 
2-3Å away from its substrate-bound position (105).  However, S96 rotates out of the catalytic 
pocket upon lid closure, breaking the hydrogen bond with the catalytic E165 and allowing it to 
swing over and induce substrate isomerization.  In the I170V structure, the inward rotation of 
S96 in the closed state is facilitated by the absence of the Ile-to-Val methyl group, and leads to 
increased hydrophilic interactions in the N hinge region.  Previous studies have shown that the N 
hinge is sensitive to both bulk and hydrophilic interference (180,182), with each inducing a 
preferentially closed lid.  The inward rotation of S96 in the I170V structure will strengthen a 
water network within the catalytic pocket, known to interact with substrate [Figure 28B].  This 
reinforced water network demonstrates a putative physical mechanism through which the 
enzyme turnover rate is reduced and substrate affinity increased [Table 3].  Collectively, these 
observations demonstrate that the shortened V170 fails to break the hydrogen bonding between 
E165 and S96 during lid closure, preferentially stabilizing this state and enhancing substrate 
affinity. 
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Figure 28.  Structural comparisons of hWT with hI170V reveal enhanced hydrogen bonding in the 
catalytic site.  Catalytic site of monomer A.  An overlay of hWT (cyan) and hI170V (pink) reveal a 90° inward 
rotation of S96, moving its distal hydrogen 2.7Å (A).  Movement is indicated by a yellow dashed line (A).  The 
rotation of S96 enhances the coordination of a catalytic water and H95 (B).  Polar interactions are indicated 
by blue dashed lines and their distances indicated (B).  Both structures are shown as cartoons, with pertinent 
residues labeled and displayed as sticks.   
4.4 DISCUSSION 
Due to the rarity of the disease and dearth of model systems, little is known about the 
pathogenesis of TPI deficiency.  We have pathologically and physically characterized a 
previously unstudied human disease-associated TPI mutation.  We found that the I170V 
mutation was genetically homozygous viable, yet when paired with a null allele was capable of 
inducing behavioral dysfunction similar to a previously described pathogenic Drosophila TPI 
point mutation (50,64).  These characteristic fly behaviors are enriched for neurological 
dysfunction, and therefore are believed to be analogs of the symptoms exhibited by human 
patients (74,75).  A reduction in catalytic activity in these mutants was predicted based on a 
previous study in yeast (62).  Yet oddly, in vitro biochemical analyses (Table 3) suggested the 
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I170V mutant should be as efficient as wild type, a result at odds with our in vivo lysate 
measurements [Figure 24A].  It is unclear as to why these results were not in congruence, but we 
cannot rule out possible affector proteins or unknown regulatory mechanisms which may be 
present in the lysates, but not the purified system.   
Seeking a molecular explanation of hTPI
I170V
 pathogenesis, a high resolution crystal 
structure revealed clear physical changes resulting from the I170V substitution which illustrate 
the molecular mechanisms responsible for our altered enzyme kinetics.  Specifically, the 
shortening of the I170 residue to V170 leads to the S96-mediated maintenance of a water 
network within the catalytic pocket during lid closure.  This water network likely stabilizes the 
enzyme in the substrate-bound state, again in agreement in with our 30-fold increase in substrate 
affinity [Table 3].  Further, the dynamic orientation of E165, and by extension the C- and N-
terminal hinges, has been linked to the breathing motions of the catalytic lid (177,184).  
Although our experiments lack the capacity to directly measure the rate constants of lid opening 
and closure, it is tempting to speculate that this catalytic water network could inhibit the opening 
rate of the lid.  Inhibiting lid opening would reduce catalytic turnover, resulting in largely closed 
loop orientations, both of which are observations we have made in our crystal structure and 
enzyme kinetic analyses [Table 3; Figure 28].   
The only previously crystallized human disease-associated TPI substitution, E104D, 
indicated a miscoordination of a conserved water network at the homodimer interface.  This 
alteration of the dimer interface elicited a reduction in hTPI
E104D
 dimerization and stability, but 
not changes in catalytic activity (63).  Our data establish altered catalytic properties as a function 
of the I170V substitution, while dimerization and stability experiments demonstrate a distinct 
increase in hTPI
I170V
 stability relative to hTPI
WT
 [Figure 26].  Further, although hTPI
I170V
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substrate affinity is increased [Table 3], the addition of a substrate analog elicited a modest 
increase in protein stability (∆Tm=1.6°C) relative to hTPI
WT
 (∆Tm=3.7°C).  These data suggest 
one of two possibilities: i) the I170V substitution selectively reduces DL-GP, but enhances GAP 
binding, or ii) hTPI
I170V
 stability is less sensitive to catalytic site occupancy.  Addressing the 
first, the catalytic area critically affected by the I170V substitution and Ser96 rotation is the 
region of the catalytic pocket occupied by the phosphate.  The positioning of this phosphate is 
conserved between DL-GP and GAP, making it unlikely that DL-GP binding would diverge 
from that of GAP as a function of the I170V substitution.  Therefore, we believe it is far more 
likely that these stability data indicate that hTPI
I170V
 is mimicking the substrate-bound 
conformation, with similar physical mechanisms underpinning its increased stability.   
Although an unanticipated and exciting result, the structure of hTPI
I170V
 does not yield 
any insight into why we observe changes in stability [Figure 29].  Experiments examining the 
relative contributions of solvent and chain entropy in this mutant would be needed to 
conclusively determine a molecular mechanism of I170V stability.  However, the confluence of 
data lead us to speculate that lid orientation is likely responsible for the changes in enzyme 
stability.  Preferential lid closure would provide additional protection from bulk solvent, and 
reduce overall solvent entropy; a result borne out by the substrate-induced stabilization of 
hTPI
WT
.  Comparatively, the preferentially closed lid of hTPI
I170V
 reduced the sensitivity to 
substrate-induced TPI stabilization.   
Irrespective of the molecular mechanism, the findings that hTPI
I170V
 induces pathology 
and is characterized by decreased catalysis and increased stability demonstrates that reduced TPI 
dimer stability alone is not the only means to achieve pathology.  These observations prompt two 
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new hypotheses regarding TPI Deficiency: i) TPI dimers and monomers are dynamically 
regulated molecules, or ii) localized, not gross TPI activity, is necessary for normal behavior.  
The former hypothesis centers on the potential for TPI dimerization or stability to be 
purposefully regulated.  In support of this hypothesis, recent reports have detailed two post-
translational modifications which have been shown to influence TPI isomerase activity and 
protein levels in vivo: phosphorylation of TPI by cyclin dependent kinase 2 (cdk2) (127), and 
methylation of R189 by protein arginine methyl-transferase 5 (PRMT5) (128).  The 
phosphorylation of TPI is predicted to occur at the solvent/dimer interface residue S20 (127), and 
we hypothesize that post-translational modifications of this residue would likely alter dimer 
interface morphology.  Additionally, R189 participates in an entirely conserved salt bridge with 
D225 at the distal ends of the homodimer.  This salt bridge has been shown to be a critical 
determinant of TPI stability (142), and methylation has been predicted to disrupt this interaction.  
Further work is needed to more clearly define the role of TPI post-translational modifications, 
but provide a tempting platform for speculation. 
Alternatively, the latter hypothesis builds upon the preeminent finding that hTPI
I170V
 has 
a dramatic effect on enzyme kinetics.  Previous work has demonstrated that a catalytically 
inactive TPI allele can complement the toxic TPI
M80T
 substitution.  This study concluded that 
TPI Deficiency neurological dysfunction and reduced longevity are not correlated with metabolic 
stress (1), yet did not exclude the possibility of catalytic microdomains.  It is currently unclear 
where such a microdomain could be critical, and to what end.  TPI activity contributes to the 
glycerol synthesis pathway, glycolysis, and the glycerol 3-phosphate NADH shuttle.  An 
assessment of human disease symptoms in each pathway fails to suggest a singular pathogenic 
catalytic mechanism.  Additional work will be needed to explore the putative importance of 
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catalytic microdomains and their contribution to the unique pathology associated with TPI 
deficiency. 
In conclusion, the data presented in this study demonstrate the pathogenic nature of a 
previously understudied human mutation, and illustrate the molecular mechanism responsible for 
its pathogenesis.  These results are critical for directing future experimentation surrounding the 
largely understudied role of TPI in animal physiology, and the pathogenesis of TPI Deficiency. 
 
 
Figure 29.  I170V crystal structure lacks insight regarding altered protein stability.  I170V fails to 
alter a conserved trans-monomeric TPI water network (A) known to alter protein stability (63).  Analyses of 
WT and I170V demonstrate similar folding and orientation of the peptide backbone (B).  Residues shown as 
sticks, colored by element, with WT labeled blue and I170V labeled pink (A).  Waters are indicated by 
unbound spheres, with WT in red and I170V in yellow (A).  Proteins displayed a cartoon with backbones 
colored as before (B); dashed line indicates the dimer interface.  
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4.5 MATERIALS AND METHODS 
4.5.1 Mutagenesis and Genomic Engineering 
The pGE-hTPI
WT
 construct was generated using human TPI (hTPI) coding region. The hTPI 
sequence was synthesized and recoded for Drosophila codon usage, while maintaining 
Drosophila intron-exon gene architecture and splicing, to ensure appropriate expression. The 
synthesized hTPI was designed to include flanking restriction sites for cloning into the pGE-
attBTPI
+
 plasmid (1). Site directed mutagenesis was performed using the QuikChange 
Lightening Site-Directed Mutagenesis Kit (Agilent Technologies). Mutagenesis primers were 
generated (Integrated DNA Technologies) to introduce an Ile-to-Val codon change at position 
170. Mutagenesis was performed with pGE-hTPI
WT
 and confirmed by sequencing. TPI GE was 
performed using previously published methods (1,99,100). Briefly, the PGX-TPI founder 
animals were mated to vasa-phiC31
ZH-2A
 animals expressing the integrase on the X chromosome 
and their progeny injected with pGE-attBhTPI
I170V
. Integration events were identified via the w
+
 
phenotype and verified molecularly. The newly synthesized alleles were outcrossed to w
1118
 for 
five generations and mated to y
1
 w
67c23
 P[y[+mDint2]=Crey]1b; D
*
/TM3, Sb
1 
to reduce the 
engineered locus. 
4.5.2 Human TPI enzyme purification 
Human TPI enzyme was purified as outlined previously (1).  Briefly, the coding sequence for 
H.sapien TPI was cloned into the bacterial expression vector pLC3 using standard techniques.  
The resulting plasmid directs expression of TPI containing N-terminal His6- and MBP tags, both 
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of which can be removed with TEV protease. TPI protein was expressed in BL21(DE3) Codon-
Plus (RILP) E. coli (Agilent Technologies) grown in ZY auto-induction media (Studier, 2005) at 
room temperature for 24–30 hours. Cells were harvested by centrifugation, lysed via 
homogenization in 25 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 5 mM imidazole, 1 mM β-
mercaptoethanol and cleared by centrifugation at 30,000 g. TPI was purified by nickel affinity 
chromatography followed by overnight TEV protease treatment to cleave the His6-MBP tag from 
TPI. A second round of nickel affinity purification was performed to separate the His6-MBP and 
TEV protease. TPI protein was further purified using cation-exchange chromatography (HiTrap-
QP) followed by gel filtration (Sephacryl S-200, GE Healthcare). Peak fractions were 
concentrated to 4–8 mg/ml in 20 mM Tris pH 8.8, 25 mM NaCl, 2.0% glycerol and 1 mM β-
mercaptoethanol using a Vivaspin concentrator (GE Healthcare). The purity was >99% as 
verified by SDS-PAGE. 
4.5.3 Gel Filtration Chromatography 
Gel filtration was performed as outlined previously (85).  Briefly, separations were performed 
with a Shimadzu high performance liquid chromatography (HPLC) system using a Superdex 
75/300 GL column (Amersham Biosciences) set to a flow rate of 0.4 ml/min at room 
temperature.  A non-denaturing mobile phase was selected consisting of 25mM NaH2PO4, 25mM 
Na2HPO4, 150mM NaCl; pH 7.0.  The column was calibrated with a Low Molecular Weight Gel 
Filtration Calibration Kit (GE Healthcare Life Sciences) according to the manufacturer’s 
instructions.  Calibration standards included Aprotinin (6.5kDa), RNAase A (13.7kDa), Carbonic 
Anhydrase (29kDa), Ovalbumin (44kDa), and Conalbumin (75kDa).  Purified TPI samples were 
diluted to 15μM in mobile phase and 100μl were injected and measured in triplicate, and their 
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elution monitored at 280nm.  Chromatography traces were collected and analyzed using EZStart 
7.3 (Shimadzu) to quantify the relative monomer and dimer populations.  Curve integration data 
were compared using a one-way ANOVA with Tukey’s post-hoc analysis. 
4.5.4 TPI Enzyme Assays 
Isomerase activity was determined using an NADH-linked assay as previously detailed (1,132). 
Initial velocity of the enzyme was calculated over a GAP (Sigma-Aldrich, St. Louis, MO, USA) 
range of 0.0094-4.23 mM; enzyme quantities as noted [Figure S1].  All kinetic measurements 
were performed three times in triplicate by monitoring the absorbance of NADH at 340 nm in a 
SpectraMax Plus 384 microplate reader (Molecular Devices).  The assay was performed using 80 
µl mixtures containing varied GAP and enzyme concentrations, 0.5 mM NADH (Sigma-
Aldrich), and 1 unit glycerol-3-phosphate dehydrogenase (Sigma-Aldrich) in 100 mM 
triethanolamine (TEA), pH 7.6.  Enzyme activity curves were normalized to reactions performed 
without GAP.  Enzyme kinetics were determined by assessing initial velocities taken during the 
linear phase of each reaction, and the data were fit to the Michaelis-Menten equation using 
nonlinear regression in Graphpad Prism 5.0b (GraphPad Software). 
Lysate assays were performed similarly.  Briefly, animals aged 1-3 days were collected 
and frozen in liquid nitrogen. Bodies lacking heads or appendages were isolated and 
homogenized in 100mM TEA pH 7.6 supplemented with cOmplete mini Protease Inhibitors 
(Roche Diagnostics). The homogenates were sonicated in an ice bath for 10min and centrifuged 
twice at 4°C for 5min at 5,000g to remove exoskeletal debris. Lysates were diluted to 0.1μg/μl in 
100mM TEA pH 7.6 + inhibitors and enzyme activity was assessed. Reaction assays were 
performed using 80μl mixtures composed of 0.5mM NADH, 0.752mM GAP, 1 unit glycerol-3-
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phosphate dehydrogenase and 1μg of lysate protein in 100mM TEA; pH 7.6.  All reactions were 
performed in both experimental and biological triplicate.  Reaction components were purchased 
from Sigma-Aldrich. 
4.5.5 Circular dichroism and thermal stability  
Circular dichroism (CD) thermal stability analysis was performed on a Jasco J-810 as outlined 
previously (63). Briefly, samples were diluted to 350µg/ml in 0.2µm nylon-filtered 20mM 
MOPS, 1mM DTT, 1mM EDTA pH 7.4, and denaturation was monitored at 222 nm over 20-
80°C at a rate of 0.267°C/min with a pitch of 0.2°C. Far-UV spectra were taken in 1X PBS at 
indicated temperatures for better resolution (63). DL-glycerol-3-phosphate (Sigma), a TPI 
substrate analog (176-178), was added to a final concentration of 5mM (185) and thermal 
stability reassessed. All spectral data were acquired 5 times per step, and three independent 
replicates were run for each experimental condition. 
4.5.6 Behavioral testing and lifespan analysis 
Mechanical stress sensitivity was examined by vortexing the animals in a standard media vial for 
20 seconds and measuring time to recovery, similar to (66,133). Thermal stress sensitivity was 
assessed by acutely shifting animals to 38°C and measuring time to paralysis, as previously 
described (65,109). Paralysis was defined as being at least a 15sec period.  All behavioral 
responses were capped at 600 seconds.  Animal lifespans were performed at 25°C as previously 
described (109). A nonparametric Student’s t test was used to assess behavior, and lifespans were 
assessed with Log-rank (Mantel–Cox) survival tests. 
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4.5.7 Immunoblots 
Animals were collected aged 1-2 days at room temperature. Ten fly heads were obtained in 
triplicate from each genotype and processed as outlined previously (86). Briefly, the fly heads 
were ground by pestle in 80 µl 2× SDS–PAGE sample buffer (4% SDS, 4% β-mercaptoethanol, 
130 mM Tris–HCl pH 6.8, 20% glycerol) and centrifuged for 5 minutes at 5000 g to pellet the 
exoskeleton.  Proteins were resolved by SDS–PAGE and transferred onto 0.45μm PVDF 
membrane. Following treatment in 1% milk PBST, the blots were incubated with anti-TPI 
(1∶5000; rabbit polyclonal FL-249; Santa Cruz Biotechnology) or anti-Beta tubulin (1∶4,000; 
rabbit polyclonal d-140; Santa Cruz Biotechnology).  The blots were washed in PBST, incubated 
in the appropriate HRP-conjugated secondary antibody, and developed using ECL (Pierce).  
Densitometric analyses of the scanned films were performed digitally using ImageJ software 
available from the National Institutes of Health.  Student’s unpaired t test was performed to 
assess differences in TPI. 
4.5.8 Protein crystallization and structural determination 
Recombinant human TPI and hTPI
I170V
 protein and was purified as described above. Initial TPI 
crystals were grown at 4 using the sitting drop vapor diffusion method against a reservoir 
solution containing 34% PEG 2000 MME and 50 mM KBr. These initial crystals were improved 
by microseeding using a reservoir solution containing 30-34% PEG 2000 MME and 50 mM 
KBr. The crystals used for data collection, grew to final dimensions of ~100 x 100 x 150 µm 
over the course of 3 days prior to harvesting. Crystals were cryoprotected by transition of the 
crystal into reservoir solution supplemented to 40% PEG 2000 MME and 20% glycerol followed 
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by flash freezing in liquid nitrogen. Diffraction data for wild type TPI were collected at the 
National Synchrotron Light Source on beamline X25 using a Pilatus 6M detector. Diffraction 
data were integrated, scaled, and merged using HKL2000 (186). Wild-type crystals belong to the 
space group P21 (a = 47.92 Å, b = 48.85 Å, c = 93.97 Å; β = 103.66°) and contain a dimer in the 
asymmetric unit. Crystals of hTPI
I170V
 belong to space group P212121 (a = 64.92 Å, b = 73.64 Å, 
c = 91.77 Å), and also contain a dimer in the asymmetric unit. Initial phases for both wild-type 
and hTPI
I170V
 were estimated via molecular replacement using a search model derived from an 
independent structure of human TPI (2VOM) (63). The model was then refined against native 
data and improved by manual rebuilding within Coot (187) combined with simulated annealing, 
positional, and anisotropic B factor refinement within Phenix. For hTPI
I170V
, isotropic B-factor 
and TLS refinement was used. Model quality for both structures was assessed using MolProbity 
(188). Structural figures were generated using PyMol (PyMOL Molecular Graphics System, 
Version 1.5.0.4, Schrödinger, LLC.). 
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5.0  DISCUSSION 
Prior to the initiation of my thesis work, very little was known about the pathogenic nature of 
TPI deficiency.  Due to the rarity of the disease and disparate patient allelic combinations, it was 
not entirely clear which TPI mutations were sufficient to cause neurological phenotypes.  Work 
in this field was often limited to description due to the dearth of primary tissue samples and a 
lack of robust model systems.  Yet in the past few years of my graduate work I have helped 
establish a genomic engineering system for the Drosophila TPI locus, and this system facilitated 
hypothesis-driven experimentation on the pathogenesis of TPI deficiency.  Establishing this 
system, I used these resources to examine whether the presence of the enzyme or its catalysis 
were most critical to the behavioral phenotypes seen in our animals.  In these initial studies I 
found that an inactive variant of TPI was capable of fully complementing our disease mutant, 
and biochemical data supported this conclusion, revealing that this complementation occurred 
without gross changes in enzyme catalysis or alleviating metabolic stress.  These data suggested 
that it was unlikely that TPI deficiency was being caused by a general metabolic defect, and 
instead pointed to the possibility that it could be due to a conformational change in the protein.  
To test this hypothesis, I worked in collaboration with the VanDemark lab to purify and 
characterize the TPI
M80T
 protein.   
Physical analyses revealed a dimerization defect associated with TPI
M80T
, a characteristic 
shared by the highly toxic human disease-associated mutation, TPI
E104D 
(63).  Independent 
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mutations at the dimer interface of TPI, TPI
T74R
 and TPI
G75E
, further underlined the relationship 
between dimer conformations and disease.  These mutations exhibited more severe phenotypes 
than our previously characterized TPI
M80T
 allele, and their behaviors suggested the possibility of 
underlying conductive or synaptic dysfunction.  Indeed, vesicle recycling experiments indicate 
synaptic dysfunction, and although I have not established a precise biochemical mechanism for 
these effects, they demonstrate that the neurological dysfunction seen in TPI Deficiency patients 
arises from a vesicle recycling defect.  Further work will clearly be needed to establish the exact 
mechanism of the pathogenesis, but my observations are the first to establish a synaptic 
phenotype in TPI deficiency.   
Finally, the last of my dissertation work sought to focus our GE system on an 
understudied human disease-associated mutation.  As mentioned earlier, prior to my work it was 
not understood whether certain human TPI mutations were sufficient for pathology.  One such 
mutation, a TPI
I170V
 missense mutation, has now been established as sufficient for eliciting 
neurological dysfunction in Drosophila.  Further, a detailed structural and biochemical analysis 
of this protein indicated a unique increase in substrate affinity, homodimerization, and thermal 
stability.  Structural analyses revealed that the I170V substitution facilitated the internal rotation 
of S96 into the catalytic pocket of TPI
I170V
.  The rotation of this S96 residue stabilized a 
hydrogen bond network within the catalytic pocket, and is responsible for the increase in 
substrate affinity and reduction in catalytic turnover.  Data from the crystal structure and stability 
assays suggest that TPI
I170V
 is preferentially in the closed lid conformation, and this closed lid is 
likely the mechanism responsible for the observed increase in enzyme stability.  These 
observations are provocative in their implications regarding cellular recognition of enzyme 
activity and protein regulation. 
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5.1 TPI PROTEIN CONFORMATION AND DISEASE 
In the last two decades several reviews have been written summarizing the collective 
observations of the community and literature surrounding TPI deficiency (26,45,48,189).  With 
the dearth of model experimental systems, these reviews have relied heavily on the initial clinical 
characterizations of the disease and a few descriptive studies of erythrocytes derived from 
patients.  This research has been critical for understanding the relationship between TPI 
mutations and the human disease, yet lacked the hypothesis-driven approaches found in 
controlled systems.  The authors of these reviews should be commended for highlighting of the 
poorly understood link between TPI activity and disease, with many citing the diverse 
observations of protein activity, cellular metabolism and protein levels.  Indeed, a review which 
structurally plotted all of the known human mutations was the first to propose the idea that 
protein conformation could be the basis of TPI deficiency pathology (45).  This hypothesis was 
followed up by a yeast molecular study by the Krobitch lab and structural/biochemical analyses 
by the Torres-Larios lab which determined the TPI
E104D
 human mutation affected protein 
dimerization and therefore quaternary structure (62,63).  These articles were the first to lend 
substantial support to the hypothesis that TPI deficiency is a conformational disease.   
Many conformational diseases are elicited by changes in protein quaternary structure, 
with the most common being gain-of-function changes leading to aggregation (138).  However, 
it has been well-established that conformational loss-of-function diseases are also possible, with 
the most prevalent being mutations in the tumor-suppressor p53.  p53 is a highly regulated 
transcription factor, intimately related to DNA repair and cell cycle progression (190,191).  
Conformational changes in p53 can result in an inability to appropriately tetramerize and bind 
DNA (192), an alteration of binding to regulatory proteins (193), changes in localization signals 
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(194), etc.  Mutations of p53 are found in approximately 50% of cancers, and almost all cancers 
influence either it or members of its network, underlining the protein’s relevance to human 
disease (195).  I propose that TPI deficiency could be elicited by a similar loss-of-function due to 
protein conformation – likely through changes in enzyme transport to distal cellular locations. 
The TPI reviews were critical in shaping my understanding of the field as I was initiating 
my experiments.  I was fortunate to be working with a whole animal model of TPI deficiency 
which allowed for such analyses, and these inspirations directed me to question whether gross 
activity and metabolism were truly necessary contributors to the behavioral and longevity 
phenotypes we saw in our Drosophila.  To this end, my initial studies focused on whether a 
depletion of TPI protein or catalytic activity were more critical determinants of Drosophila TPI 
deficiency.  I engineered a constitutively inactive variant of TPI and sought to assess 
complementation of our TPI
M80T
 mutant allele; a general strategy employed in the evaluation of 
several molecular fields (196-198).  The results of these experiments indicated the inactive TPI 
was able to fully complement TPI
M80T
.  Further experiments established that this was not due to 
changes in gross lysate TPI activity, TPI
M80T
 protein levels, or an insect marker of metabolic 
stress.  Later experiments established that the TPI
M80T
 mutation reduced dimerization of TPI, and 
independent mutations of TPI at the dimer interface were also sufficient to elicit disease.  These 
same experiments established that some of the most toxic TPI alleles were characterized by 
dramatically more lysate isomerase activity than completely healthy animals, firmly establishing 
that gross catalytic activity is not predictive of disease presence or severity, and instead 
suggesting that protein conformations are more likely the critical determinants of disease. 
To contrast these results, I selected a human disease-associated mutation at the catalytic 
site for further evaluation.  This point mutation, TPI
I170V
, was examined in the context of the 
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human protein in Drosophila for its sufficiency to elicit pathology, as it had only ever been 
identified in a trans-heterozygote state in humans, paired with a TPI
E104D
 allele.  We again saw 
pathology in these hTPI
I170V
 animals as contrasted by hTPI
WT
.  Detailed characterization of 
enzyme kinetics revealed that the mutation elicited a marked change in enzyme activity, with 
I170V eliciting an increase in substrate affinity and a decrease in catalytic turnover.  Noting that 
dimerization can influence catalytic activity, we sought to examine the converse relationship – 
whether changes in the catalytic site could influence dimerization and stability.  Gel filtration 
results indicated that hTPI
I170V
 exhibited an increase in dimerization and enzyme stability.  In 
collaboration with the VanDemark lab, X-ray crystal structures of each protein were generated 
and analyzed.  Resolutions of 1.6 and 2.0Å were achieved in the WT and I170V structures, 
respectively, allowing near-atomic comparisons of protein conformations.  The crystal structure 
indicated that the shortening of the I170 residue to V170 facilitated the rotation of a proximal 
S96 into the catalytic site, reinforcing a water network within the catalytic pocket.  This water 
network increased substrate affinity, reduced enzyme turnover, and led to a generally closed lid 
conformation.  The crystal structure failed to reveal any obvious changes at the dimer interface.  
Indeed, the only changes observed at the critical dimer interface loop 3 revealed backbone and 
therefore residue shifts of 0.4-0.6Å, just outside the cumulative resolution error of 0.4Å for any 
pairwise comparison of these structures.  However, thermal stability experiments suggested that 
the I170V substitution elicited a protein conformation also induced by catalytic site occupancy.  
These data collectively suggest that an occupied or closed catalytic lid yields a more stable 
enzyme.  The basic implications of active site conformation and putative changes in stability are 
intriguing, and could be a means for a protein to autonomously regulate its own turnover.  
Extending this type of analysis to similar soluble, oligomeric, cytosolic proteins could have 
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stimulating implications on the turnover of cytosolic substrates, as comparatively little is known 
these regulatory mechanisms versus that of the endoplasmic reticulum.       
5.2 DIMERIC COOPERATION AT THE CATALYTIC SITE 
One of the key results that I have struggled with during the course of my thesis has been the 
inexplicable differences in pathology as a result of various TPI structural modifications and 
allelic combinations.  In particular, I have found it difficult to explain the healthy behavior of 
TPI
T74R
/TPI
∆cat
 and TPI
M80T
/TPI
∆cat
, versus the moderate behavioral dysfunction of 
TPI
G75E
/TPI
∆cat
 and the complex behavioral and longevity phenotypes of TPI
T74R,G75E
/TPI
∆cat
.  
The capacity of an inactive enzyme to rescue two severe mutant TPI alleles is astonishing.  Yet 
an inability for this same inactive allele to similarly complement two other dimer mutations has 
led me to conclude that TPI
∆cat
 is not alone sufficient for adult rescue, suggesting requisite 
interactions within the heterodimer.  Again, the pathology does not seem to be determined by 
gross isomerase activity, and an analysis of heterodimer populations failed to suggest an 
underlying mechanism.  Further, the capacity of a catalytic site mutation, TPI
I170V
, to similarly 
elicit pathology cumulatively suggests the importance of microdomains of activity as a 
pathological mechanism.  Indeed, a conformational change in the protein could merely affect 
trafficking and/or stabilization of small pools of active heterodimers at a requisite site.  However, 
if one proposed that the inactive enzyme rescued pathology through increased trafficking of the 
still-active allele (TPI
T74R
/TPI
∆cat
 for example), then it would follow that this interaction would 
likely be stronger than a comparatively poorly rescued variant (TPI
G75E
/TPI
∆cat
) [Figure 30].  
However, coimmunoprecipitation experiments detailed almost the opposite phenomenon.  
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Clearly physical interactions alone do not explain the complementation of the disease 
phenotypes.  Yet if activity is to be achieved by the heterodimer, how could this occur in 
TPI
T74R
:TPI
∆cat
 and TPI
M80T
:TPI
∆cat 
but not TPI
T74R,G75E
:TPI
∆cat
? 
To address putative changes in heterodimer catalysis I sought to analyze the crystal 
structures and known mechanisms of dimeric cooperation and TPI catalysis.  The dimer interface 
of TPI is composed of a mixture of hydrophobic and hydrogen bond interactions which 
ultimately contribute toward the rigidification of the catalytic site of each monomer (199,200).  
Hydrogen bonds established by water molecules sequestered at the dimer interface further 
facilitate this dimeric cooperation, and are themselves participants in the catalytic process (201).  
To help explain this cooperation, the monomers involved in this interplay will be referred to as A 
and B.   
The cooperative nature of TPI catalysis is best exemplified by the extension of the 3
rd
 
loop of TPI[A] toward the catalytic site of its partner [B].  The residues of this loop are entirely 
conserved and catalytic simulations suggest that T74[A] flips “in” and “out” toward its dimer 
partner’s catalytic site, alternating the coordination of a catalytic H95[B] (21).  The alternating 
nature of this interaction allows the substrate to facilitate rapid de- and re-protonation of E165[B] 
and H95[B] in sequence.  This shuttling of protons between these catalytic residues is 
fundamental to the isomerization mechanism (202).  Additionally, hydrophobic interactions 
provided by non-polar members of the 3
rd
 loop [A] support the appropriate alignment of a 
catalytic N10[B] and K12[B] which are required for substrate binding and stabilization of 
substrate transition states (18).  Without these hydrophobic support mechanisms it has been 
demonstrated that the active site of the monomer becomes highly flexible, resulting in dramatic 
reductions in substrate affinity and catalytic capacity (18).   
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Each catalytic site within the [A]:[B] dimer is independent of the other; inactivation of 
one catalytic site does not influence the substrate affinity or catalysis of the other unless the 
dimer interface is perturbed (203).  This observation is important considering the nature of the 
proposed orientation of the TPI
T74R
 mutation.  When first described, the T74R[A] mutant was 
predicted to fit within the bottom of the catalytic site of the [B] monomer when a dimer was 
forced by a modeling algorithm (19).  Experimentally it was determined that the T74R mutation 
conveyed a strong disruption of the dimer interface leading to a largely monomeric population of 
TPI in vitro.  To obtain a fully monomeric population of protein to examine, the authors 
generated an additional mutation at the G75 position, and the double mutant was confirmed to be 
completely monomeric (19).   
I believe that the nuances in the positioning of these dimer interface mutations could 
ultimately be responsible for the complete phenotypic rescue via a catalytically inactive TPI to 
the TPI
M80T
 and TPI
T74R
, but not the TPI
G75E
 and TPI
T74R,G75E
 alleles.  Of the three mutations 
examined, M80T[A] and T74R[A] would be predicted to elicit their catalytic defects by i) 
reducing dimer affinity and ii) modulating the integrity of the catalytic pocket of TPI[B].  
Conversely, G75E[A] is hypothesized to i) disrupt the 3
rd
 loop flexibility provided by the G75 
(21) thereby conveying stress back into TPI[A] upon dimerization, and ii) project into and 
displace important waters sequestered in the dimer interface which contribute to the catalysis of 
both [A] and [B].  These alternative positions, when heterodimerized with an inactive TPI[B], 
would lead to various catalytic outcomes for [A].  Importantly, both M80T[A] and T74R[A] 
would be left with an intact catalytic site [A] which if localized appropriately could contribute a 
modicum of isomerase activity [Figure 27].  Further, the displacement of K12[B] from ∆cat[B] 
may actually generate an amenable pocket for T74R[A].  Conversely, TPI isoforms containing 
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the G75E[A] mutation would continue to exhibit a dearth of local activity even when paired with 
an inactive partner[B]. 
5.3 SYNAPTIC TPI DEFICIENCY AND BEHAVIOR 
Measurements of lysate isomerase activity have firmly established that gross isomerase activity 
is not predictive of presence or severity of TPI Deficiency, yet allelic interactions suggest some 
role for catalytic activity in this disease.  These data could indicate the formation of catalytic 
microdomains [Figure 30] or differential enrichment of activity within specific tissues, both of 
which would be impossible to discriminate using our lysate isomerase assay.  FlyAtlas – a tissue-
based microarray survey of Drosophila gene expression – failed to detect a dramatic enrichment 
of TPI mRNA in the larval or adult CNS relative to the fly as a whole (204), suggesting that if 
tissue-specific differences in TPI activity were the culprit then regulation of these differences 
would occur at a translational or protein stability level.  Based on the ubiquity of TPI expression, 
I would more simply suggest that if tissue-specific effects are occurring it is more likely that 
unknown secondary factors are contributing to these events, possibly forming microdomains of 
necessary activity.  For example, aldolase is another glycolytic enzyme which is expressed 
ubiquitously and at relatively consistent levels (204).  However, its localization to the endosome 
is required for vacuolar H
+
-ATPase (V-ATPase) assembly and function (119,120,205).  Though 
V-ATPase function is important in all tissues, a loss of rapid acidification of vesicles, or poor 
maintenance of the proton gradient in endosomes could lead to dysfunction in receptor dynamics 
as well as vesicle loading.   
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Previously, the only secondary factors known to directly interact with TPI were the 
cytoskeletal protein cofilin and the sodium-potassium exchanging ATPase (Na,K-ATPase).  
Work in mammalian systems described the localization of TPI at the Na,K-ATPase by cofilin, 
and concluded that this was to establish a glycolytic complex to feed the ATPase (206).  
Experiments performed in the lab prior to my integration were unable to identify cofillin:TPI 
complexes [data not shown].  Additionally, my TPI::Na,K-ATPase genetic interactions yielded 
unclear results.  Interestingly though, previous studies in our lab have detailed the sequestration 
of TPI
M80T
 by heat shock proteins 70 and 90 (Hsp70, Hsp90) (86).  In this way, it is possible that 
the differences in TPI
∆cat
 complementation could be due to changes in this sequestration.  Indeed, 
my discussion in Chapter 3 centered on the possibility of sequestration and degradation of TPI 
dimer mutations prior to their distal transport [Figure 30].  These assertions were based largely 
on in vitro analyses which demonstrated that these substitutions altered protein stability.  Future 
experiments could focus on the capacity of TPI
∆cat
 to protect TPI mutants from sequestration by 
chaperones.  Additionally, changes in enzyme stability could be assessed in vivo through 
cotransformation of yeast with differently tagged variants of TPI dimer mutants and TPI
∆cat
.  
Finally, restored distal trafficking could be measured in vivo using genetic complementation of 
fluorescently-tagged mutants. 
To identify candidate tissues and subcellular locations where TPI function could be most 
critical, I turned to the mutant phenotypes.  The vacuolar neuropathology of our TPI
M80T
 mutant 
Drosophila suggested the possibility of either neural or glial dysfunction, while their behavior 
left open the possibility of a muscular component.  As described earlier, mechanical stress 
sensitivity and thermal stress sensitivity are phenotypes enriched for neurological dysfunction 
(72); several mutations that affect primarily glia or neurons have been shown to result in these 
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behaviors.  Conversely, few mutations specifically influencing muscles have been established to 
do the same, with one of the few being a mutation in the sarco/endoplasmic reticulum calcium 
ATPase (SERCA) (207).  Though SERCA mutations elicit thermal stress sensitivity, the 
hallmarks of this SERCA phenotype are basal hypoactivity, which is slowly exacerbated at the 
non-permissive temperature with no accompanying mechanical stress paralysis or seizures. 
Therefore the confluence of both thermal- and mechanical dependant phenotypes, as well 
as the neuropathology provided the basis for looking specifically at the nervous system.  Tissue-
specific rescue experiments, often a strength of the Drosophila model system, were also 
examined.  However, it was found that the initial transposon-mediated placement of the UAS-
TPI transgenes exhibited substantial leak expression, confounding the rescue data.  These results 
were unfortunate and precluded a proper genetic anatomical dissection.  Recently, the McCabe 
laboratory has developed a new attB-mediated transgenic vector with gypsy insulator sequences 
to help protect the construct from chromatin positional effects and cis-regulatory elements (208).  
The attB sequences facilitate directed transgene placement in previously established locations in 
the genome (97,98).  Additionally, noting the propensity for insulators to enhance leak when 
combined with the widely used UAS hsp70 promoter (209,210), the authors leveraged a 
synthetic promoter construct in conjunction with the UAS system (211).  Using these constructs, 
the authors established exquisite transgenic regulatory control in a number of diverse tissues, 
with transgenes positioned on different chromosomes (208).  This system would likely be perfect 
for addressing our previous transgenic difficulties, facilitating a proper analysis of tissue-specific 
requirements of TPI and its relationship to longevity and behavior. 
Though our anatomic transgenic strategies failed to establish a tissue-specific source of 
dysfunction, the extreme thermal stress dependant phenotype of TPI
T74R
 suggested a neuronal 
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source.  As mentioned earlier, this type of acute phenotype has only been described in mutants 
which influence neural conductance or synaptic properties.  An analysis of vesicle recycling at 
the synapse revealed a conditional inhibition of endocytosis under thermal stress [Chapter 3].  
This progressive reduction in recycling was not observed at room temperature, and could be 
complemented by TPI
∆cat
, much like the adult thermal stress-dependent paralysis [Chapter 3].  
These data are the first to demonstrate that TPI Deficiency elicits neurologic dysfunction through 
a reduction in synaptic vesicle recycling.  TPI has not previously been directly linked to any of 
the endocytic machinery, but a recent study indicated that vesicle recycling was the largest 
consumer of ATP at the synapse (135).  This study established that glycolysis was a strong 
facilitator of vesicle recycling, and that glycolytic inhibition resulted in a quick cessation of 
vesicle endocytosis (135).  I lacked the experimental time necessary to identify the exact 
biochemical mechanism, but predict that if TPI mutations reduce vesicle endocytosis through an 
inhibition of synaptic glycolytic flux, we should be able to phenocopy our mutant results in 
TPI
WT
 animals through the administration of glycolytic inhibitors such as 2-deoxyglucose.  
Similarly, bath applications of ATP or GTP with the addition of membrane pore-forming 
antibiotics should facilitate a conditional rescue of the mutant phenotypes.   
Interestingly, Rangaraju and colleagues found that glycolytic inhibition had a greater 
influence over vesicle recycling than inhibition of OXPHOS (135).  The conclusions of this 
study were hinted at previously by Verstreken and colleagues, wherein the authors were able to 
inhibit synaptic mitochondrial transport, yet still achieve normal vesicle recycling (212).  Finally, 
previous work performed by the Littleton group also indicated a reduction in vesicle recycling 
through a mutation in phosphoglycerate kinase, an ATP-producing step of glycolysis (158).   
 116 
Collectively, these studies suggest that glycolytic ATP is the primary energy source for vesicle 
recycling, and these findings strongly support a catalytic role for TPI in vesicle recycling.   
As mentioned previously, Drosophila TPI Deficiency is a multi-phenotype condition, 
consisting of both mechanical- and thermal-stress induced seizure and paralytic phenotypes.  The 
work presented in Chapter 3 demonstrates a physiologic mechanism responsible for the thermal-
stress induced paralysis, but does clarify the pathogenesis of the mechanical-stress induced 
seizures.  A survey of mechanical-stress sensitive mutants reveals they are enriched for 
metabolic and mitochondrial mutants, including genes encoding citrate synthase (213), 
ethanolamine kinase (214), a mitochondrial ribosomal protein (215), ATP6 of the electron 
transport chain (216), mitochondrial superoxide dismutase 2 (217), triosephosphate isomerase 
(50), and the adenosine nucleotide translocase (218).  Many of these reports originally focused 
on the bioenergetic effects of these mutations, but an emerging theme among these alleles has 
been an increasingly prevalent thread of altered cellular redox chemistry.   
In the TPI
M80T
 mutant it has been shown that lysate NAD
+
/NADH ratios shift toward an 
oxidative state (35).  A buildup of cytosolic NAD
+
 or NADP
+
 could have dramatic consequences 
on general excitability through their capacity to regulate various K
+
 channels and TRPM2.  
Mutations in GAPDH, the primary cytosolic source of NADH, have not been identified as a 
source of disease in human patients.  This lack of disease-association, coupled with the central 
importance of GAPDH as a regulator of vesicle transport (219), cytosolic NADH production, its 
contributions as a transcription factor (123) and regulator of apoptosis (220) all suggest lethality.  
However, inhibiting TPI function would have a clear impact in NADH production through its 
restriction of glycolysis.  In this way, it is possible that TPI dysfunction may specifically restrict 
NADH production.  Accumulation of NAD
+
 in the cytosol could activate K
+
 or TRP channels, 
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thereby altering circuit excitability.  Two-electrode voltage clamp experiments at the Drosophila 
neuromuscular junction would facilitate the analysis of mini excitatory post-junctional currents, 
as well as summation properties of excitability at the presynaptic terminal.  Failure rates when 
following train stimuli could also suggest conductance defects.  Finally, if an aberrant phenotype 
is revealed, the nature of these preparations would allow the introduction of pharmacologic redox 
modifications, facilitating an examination of redox status in these specific mutants.  
 
 
Figure 30.  Hypothesized model of TPI behavioral pathogenesis.  Long-distance transport of 
glycolytic proteins is required for their delivery to the boutons.  Wild type TPI (green) is transported to the 
terminal, enhances glycolytic flux, maintains cellular redox potential, and facilitates synaptic vesicle 
endocytosis.  Conversely, an unstable (red) and inactive (blue) TPI are sequestered and degraded, and/or 
unable to support chronic endocytosis and appropriate redox chemistry.  I hypothesize that the genetic 
complementation of the inactive and unstable variants are likely capable of restoring transport and localized 
activity at the bouton (red/blue). 
 
To support any potential synaptic redox data, measurements of NAD
+
 and NADH have 
been performed optically in vivo and in in vitro cell cultures (221-223).  These strategies could 
be a means to link the complementation of TPI mutants with a biochemical mechanism.  The 
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capacity of an inactive allele of TPI to fully complement the behavioral defects of two dimer 
interface TPI mutants (TPI
T74R
, TPI
M80T
), but incompletely attenuate two others (TPI
G75E
, 
TPI
T74R,G75E
) suggested the necessity of heterodimer interactions.  Yet coimmunoprecipitation 
experiments assessing heterodimer populations suggested no obvious role for heterodimers.  
Lysate measurements of protein levels, enzyme activity, and protein-protein interactions may not 
reflect the events occurring at a distal element like the synapse.  It is possible that the inactive 
allele provides complementation through a small population of heterodimers exhibiting a 
structural interaction – as outlined previously – to restore localized catalytic activity [Figure 30].  
This type of catalytic influence could provide the means to restore robust production of cytosolic 
NADH at critical microdomains at the synapse or in the axon [Figure 30].  Indeed, future 
experiments will require examination of localization and quantification of TPI populations at the 
nerve terminal.  This will be accomplished by optical measurements of C-terminal CFP tags I 
have recently added to each of the TPI dimer interface mutations.  Further, genetic interactions 
with the inactive allele could be assessed for the capacity to modulate the presence of the active 
TPI variants at the synapse, perhaps through small changes in stability, increased trafficking, or 
protection from sequestration.   
5.4 EVOLUTIONARY MAINTENANCE OF TPI DYSFUNCTION 
An interesting observation made by Arthur Schneider, the patriarch of TPI deficiency research, 
has been the wide-spread persistence of loss-of-function mutations within the TPI gene (26).  Dr. 
Schneider’s work has detailed up to a 40% prevalence of promoter mutations in African-
American populations, and roughly 2-4% in European and Asian populations (55).  The 
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pervasiveness of these mutations in the face of their homozygous lethality and disease has been 
extremely curious, resulting in several epidemiologists to suggest an advantage – though clearly 
not a selection – for the heterozygous condition.  My studies have established a definitive 
survival advantage for Drosophila heterozygous for a loss-of-function mutation at the dimer 
interface.  These experiments were initially meant to probe possible dominant negative effects of 
the dimer interface mutations, yet their data reveal the first demonstration of a distinct 
heterozygote advantage. 
Given the role of TPI in metabolism, it is likely that this extension in longevity is 
achieved through a well-established means of caloric restriction.  Indeed, a population survey of 
glycolytic loss-of-function revealed a relatively high level of genetic maintenance for TPI and 
pyruvate kinase dysfunction in particular (56).  Decades of work supports this idea that caloric 
restriction extends longevity, though the mechanisms responsible for this extension have been 
hotly debated.  It has been proposed that caloric restriction extends longevity by several possible 
means: reduced oxidative stress, reduced DNA damage, and hormesis.  Based on TPI’s 
established ability to reroute glycolytic intermediates through the pentose phosphate pathway 
(PPP), I would contend the partial loss-of-function likely reduced oxidative stress in our animals, 
though I have no experimental data to support this assertion. 
5.5 NEW FRONTIERS IN GENOMIC ENGINEERING 
Little of the science presented here would have been possible if not for genomic engineering 
(GE).  The GE used in these studies is an incredibly powerful technique for the evaluation of a 
single gene.  As has been shown previously, the true value of this approach is its rapid generation 
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of diverse alleles once the founder line has been established.  Importantly, all of these newly 
generated alleles utilize endogenous regulatory mechanisms to achieve normal spatial, quantal, 
and temporal regulation.  These alleles can then be compared in similar genetic backgrounds to 
facilitate beautiful genetic experiments featuring the perfect controls.  Further, the use of 
endogenous promoter elements ensures that your work will not be complicated by possible 
overexpression or misexpression artifacts.  Transgenic overexpression is a well-established 
danger for any molecular geneticist, as you are biasing the evaluation of your molecule in the 
face of its poorly understood mechanisms of action.  For example, if your protein of interest were 
to form stoichiometric protein complexes, the overexpression of said transgene could have 
deleterious effects on the purposeful regulation of its partners.  Scaffolding molecules such as the 
sodium-hydrogen regulatory exchange factor1 (NHERF1) (224) and post-synaptic density 
protein 95 (PSD95) (225) are difficult to study in part due to the importance of stoichiometry.  
Further, overexpression of wild type could fail to achieve its desired effect without compensatory 
amplification of its complex partners, resulting in a falsely negative result.  A simple example of 
these principles can been seen in the expression of the Na,K-ATPase.  The Na,K-ATPase is 
composed of two primary subunits, an alpha and a beta.  The alpha subunit is the primary 
catalytic component of the ATPase, yet it will not leave the endoplasmic reticulum without 
complexing with beta for transport (226).  In this way, overexpression of alpha without beta 
could result in false negative results.   
Another pitfall of traditional transgenic expression is the use of linked expression 
systems, wherein you leverage an independent promoter to drive the expression of your 
transgene.  Using a linked expresser system exposes you to misexpression of your molecule in 
tissues for which it may lack a function or elicit a new one.  For example, genes such 
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hemoglobin perform diverse roles depending on the tissue in which it is expressed.  
Hemoglobin’s function as an oxygen-carrier in erythrocytes is well-defined.  However, its ability 
to bind other gas molecules has recently implicated hemoglobin as a regulator of nitric oxide 
signaling between the vasculature and muscle (9-11).  Additionally, its function as a metal 
chelator could deplete important tissues of vital cofactors necessary for other protein functions.  
In this manner, conclusions made from an incompletely characterized promoter could achieve 
off-target effects, necessitating the utilization of multiple redundant drivers for the confirmation 
of tissue-specificity.  However, all of these concerns have been anticipated in the genomic 
engineering system, as the critical viral integration site was knocked into the endogenous gene 
locus. 
Yet there are definite drawbacks to the implementation of the genomic engineering 
technology.  In particular, the inefficiencies of homologous recombination have been well-
documented, and often discourage the inexperienced from utilizing these powerful genetic 
technologies.  Upon initiating an HR project, a scientist has little way of knowing how amenable 
the targeted gene locus will be to recombination.  To this end, leveraging a genetic lesion 
technology in conjunction with the attP knock-in could be a tremendous tool for enhancing the 
efficiency of founder line generation.  The new CRISPR system utilizes an RNA-Cas9 
methodology to elicit guided double strand breaks in the genome (227,228).  This system has 
been lauded as a new and highly efficient means of generating targeted gene knockouts, yet its 
leverage toward genomic engineering would be of much greater utility. 
The introduction of both 5’ and 3’ double strand breaks within the genomic engineering 
homology arms would dramatically increases the rate of homologous repair, thus increasing the 
knock-in rate to generate the founder lines (229,230).  The challenges of such a strategy are the 
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generation and administration of the targeted guide strand RNAs, necessitating embryonic co-
injection of these constructs with linearized pGX constructs for the initial recombination event 
(229,230).  Incredibly, the authors utilized two guide RNA-targeted Cas9s to cleave 5’ and 3’ 
their desired 4.6kb gene locus, and used a simple 160 nucleotide (nt) single stranded donor with 
50nt homology arms to mediate a 3.3% replacement of their gene (229).  This combinatorial 
strategy could have dramatic effects on the time and monetary investments required for genomic 
engineering.  However, this is clearly a mutagenesis-based, reductionist approach, and thus has 
inherent limitations. 
5.6 MUTAGENESIS: FORWARD, REVERSE, AND EVERYTHING IN BETWEEN 
Since the establishment of modern genetic research by Thomas Hunt Morgan and his students, 
mutagenesis has been a tool for the investigation of genome organization as well as its content.  
Much of the fundamental work on the organization of chromosomes, genes, and heredity was 
first performed using phenotypic markers derived from mutations.  Yet upon the establishment of 
the gene as a discrete entity, forward genetics has been a means to expand our understanding of 
biology.  Through the induction of both gain-of-function and loss-of-function mutations, 
generations of scientists have probed the biological functions of our increasingly broad catalog 
of genes.  This forward genetic strategy has consistently pushed the boundaries of our 
understanding and remains one of the primary mechanisms of discovery-based science.   
Yet as molecular technology has advanced, we have developed and refined our 
understanding of genetic architecture, as well as the molecules responsible for its persistence.  
The identification of nucleic acids and the genetic code, the polymerases responsible for its 
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replication, and the repair mechanisms which maintain integrity were all landmark discoveries 
which have facilitated our current understanding of the gene.  In turn scientists have taken these 
discoveries and leveraged them into technologies with which to intentionally modulate the gene 
with the goal of intentionally changing its content, yielding the field of reverse genetics.   
In the course of my thesis work I have utilized observations and techniques owing from 
both forward and reverse genetic principles.  The impetus for my thesis work, the TPI
M80T
 
(sugarkill – TPIsgk) allele, was first identified in a forward genetic screen.  Yet the entirety of my 
dissertation research has been a tour de force in reverse genetics – utilizing a structure-function-
physiology-behavior experimental paradigm.  I have endeavored as a reductionist to relate 
changes in protein structure to important phenotypic consequences.  I have felt that working 
within a model system which allowed me to observe obvious whole-animal phenotypes was an 
important strategy for ensuring the impact of my experiments, maintaining their biological 
importance.  Yet in reflection on my thesis work, I feel that I relied too heavily on these reverse 
genetic principles, at times to the exclusion of good observation-based investigative science. 
My experience with reverse genetic approaches has left me with an intimate 
understanding of its strengths and weaknesses.  I have leaned heavily on structural biology to 
develop hypotheses surrounding physical TPI regions of putative biological importance.  Yet 
from my mutagenesis experiments I have found that there are seemingly endless ways of 
disrupting function, and the means to define uniting principles are not always obvious.  The core 
of this problem is inherent in the complexity of my in vivo system.  Genes are not singly 
demarcated entities within a larger framework of the chromosome.  Genes are integrated 
components of biology which cumulatively lead to a complex interactive system.  Genomic 
modifications of a single nucleotide within the framework of an organism will lead to 
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complications arising from not only its particular alteration, but that of its affectors and effectors.  
Reverse genetics is the most appropriate approach when asking questions with clearly defined 
players.  How does protein X interact with protein Y?  How does enzyme Q catalyze the 
isomerization of substrate R?  Yet in my case, I was making observations not merely at the 
biochemical level, but within the context of biology.   
I was performing experiments with reductionist approaches, yet my initial observation of 
complementation with a catalytically inactive allele clearly demonstrated an ignorance of all the 
affectors and effectors of TPI.  I continued my reverse genetic approach, establishing that 
dimerization defects were sufficient to elicit pathology, but spent too much time in this mindset 
as I struggled with interpreting my genetic interactions.  It was not until the end of my 
dissertation work that I retooled and took an observation-based investigative angle.  I consider it 
extremely unfortunate that it took me so long to initiate my experiments looking at synaptic 
dynamics, though I consider it one of the more important turning points for my science and my 
development as a scientist.  Observation-based science is extremely valuable in generating 
questions with testable hypotheses, which can then utilize reverse approaches; and the role of 
forward genetics is simply the means to make novel observations.  Clearly there is no one 
experimental approach that is more valuable than the others – each has its strengths and 
weaknesses – and in reflection, I think good science is simply the recognition and application of 
whatever approach is necessary to address the question at hand.  …with appropriate controls of 
course. 
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